Amarantus BioScience (AMBS) 10-K 16 May 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	May. 11, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	Amarantus Bioscience Holdings, Inc.
Entity Central Index Key	1,424,812
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 42,400,694
Entity Common Stock, Shares Outstanding		67,507,073

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 176	$ 214
Deferred financing fees	85
Prepaid expenses and other current assets	567	$ 402
Total current assets	828	616
Non-current assets:
Property and equipment, net	115	145
Intangible assets	2,861	1,497
Goodwill	7,967
Total non-current assets	10,943	1,642
TOTAL ASSETS	11,771	2,258
Current liabilities:
Accounts payable and accrued liabilities	$ 7,723	3,502
Accounts payable - Regenicin		2,550
Related party liabilities and accrued interest	$ 257	252
Accrued interest	195	$ 25
Notes payable	1,000
Senior secured convertible notes payable, net of discount $3,854	1,398
Derivative and warrant liability	5,098
Share-settled debt	521
Total current liabilities	16,192	$ 6,329
Deferred tax liability	1,113
Total liabilities	17,305	$ 6,329
Series H, $1,000 stated value; 10,000 shares designated; 2,816 and 0 issued and outstanding as of December 31, 2015 and December 31, 2014, respectively; aggregate liquidation preference of $3,154	$ 3,154
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY (DEFICIT):
Common stock, $0.001 par value, 35,000,000 authorized; 21,177,353 and 5,615,000 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively	$ 21	$ 6
Additional paid-in capital	74,767	45,886
Accumulated deficit	(92,241)	(55,183)
Total stockholders' equity (deficit)	(8,688)	(4,071)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) AND TEMPORARY EQUITY	$ 11,771	$ 2,258
Series A Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock
Series B Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock
Series C Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock	$ 1	$ 1
Series D Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock		1,169
Series E Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock	$ 8,764	$ 4,050
Series G Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Senior secured convertible notes payable discount		$ 3,854
Common stock, stated value	$ 0.001	$ 0.001
Common stock, shares authorized	35,000,000	35,000,000
Common stock, shares issued	21,177,353	5,615,000
Common stock, shares outstanding	21,177,353	5,615,000
Convertible Preferred Stock
Preferred stock, stated value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Series A Preferred Stock
Preferred stock, stated value	$ 0.001	$ 0.001
Preferred stock shares, designated	250,000	250,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series B Preferred Stock
Preferred stock, stated value	$ 0.001	$ 0.001
Preferred stock shares, designated	3,000,000	3,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C Preferred Stock
Preferred stock, stated value	$ 0.001	$ 0.001
Preferred stock shares, designated	750,000	750,000
Preferred stock, shares issued	750,000	750,000
Preferred stock, shares outstanding	750,000	750,000
Series D Preferred Stock
Preferred stock, stated value	$ 1,000	$ 1,000
Preferred stock shares, designated	1,300	1,300
Preferred stock, shares issued	0	1,299
Preferred stock, shares outstanding	0	1,299
Series E Preferred Stock
Preferred stock, stated value	$ 1,000	$ 1,000
Preferred stock shares, designated	13,335	13,335
Preferred stock, shares issued	9,766	4,500
Preferred stock, shares outstanding	9,766	4,500
Preferred stock, liquidation preference, value	$ 12,480	$ 12,480
Series G Preferred Stock
Preferred stock, stated value	$ 5,000	$ 5,000
Preferred stock shares, designated	10,000	10,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series H Preferred Stock
Preferred stock, stated value	$ 1,000	$ 1,000
Preferred stock shares, designated	10,000	10,000
Preferred stock, shares issued	2,816	0
Preferred stock, shares outstanding	2,816	0
Preferred stock, liquidation preference, value	$ 3,154	$ 3,154

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net revenues:
Operating expenses:
Research and development	$ 13,256	$ 13,762
General and administrative	11,565	7,592
Total operating costs and expenses	24,821	21,354
Loss from operations	(24,821)	(21,354)
Other income (expense):
Interest expense	$ (2,228)	(813)
Loss on issuance of common stock		(260)
Loss on issuance of warrants		(3,867)
Loss on extinguishment of convertible debt	$ (1,296)	$ (1,250)
Loss on issuance of senior secured convertible promissory notes	(1,645)
Change in fair value of warrants & derivatives liabilities	4,105	$ 317
Change in fair value of share-settled debt	(246)
Change in fair value of earn-out liability	$ 917
Other expense		$ (50)
Total other income (expense)	$ (393)	(5,923)
Net loss	(25,214)	(27,277)
Dividends declared on preferred stock	(3,595)	$ (875)
Deemed dividends on convertible preferred stock	(8,249)
Net loss applicable to common stockholders	$ (37,058)	$ (28,152)
Net loss per share applicable to common stockholders - basic and diluted	$ (4.17)	$ (5.71)
Weighted average shares used in computing basic and diluted loss per share	8,877,924	4,926,338

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2013	$ (7,519)	$ 1	$ 4	$ 19,508	$ (27,032)
Beginning Balance, Shares at Dec. 31, 2013		750,000	3,827,813
Common stock issued to acquire intangible assets	354			354
Common stock issued to acquire intangible assets, Shares			36,667
Common stock issued to acquire in-process research and development	3,000			3,000
Common stock issued to acquire in-process research and development, Share			250,000
Common stock issued in settlement of accounts payable	68			68
Common stock issued in settlement of accounts payable, Shares			5,357
Common stock issued in private placement	3,074			3,074
Common stock issued in private placement, Shares			200,274
Common stock issued in consideration of commitment fees for equity financing	516			516
Common stock issued in consideration of commitment fees for equity financing, Shares			43,120
Deferred commitment fee for equity financing reclassified upon stock issuance	(518)			(518)
Common stock issued upon conversion of 8% convertible debentures, including accrued interest	8,423		$ 1	8,422
Common stock issued upon conversion of 8% convertible debentures, including accrued interest, Shares			576,489
Common stock issued upon conversion of convertible promissory notes, including accrued interest	130			130
Common stock issued upon conversion of convertible promissory notes, including accrued interest, Shares			46,252
Common stock issued for extension of maturity of demand promissory note payable	20			20
Common stock issued for extension of maturity of demand promissory note payable, Shares			1,785
Common stock issued for Series D convertible preferred stock dividend				103	$ (103)
Common stock issued for Series D convertible preferred stock dividend, Shares			23,100
Loss on issuance of common stock	260			260
Common stock issued upon exercise of common stock warrants	4,975		$ 1	4,974
Common stock issued upon exercise of common stock warrants, Shares			552,777
Deferred funding costs charged to equity upon termination of advisory agreement	(190)			(190)
Loss on issuance of warrants	3,867			3,867
Series E convertible preferred stock issued, net of issue costs of $43	3,507	$ 3,550		$ (43)
Series E convertible preferred stock issued, net of issue costs of $43, Shares		3,944
Series E convertible preferred stock issued to retire demand promissory note	$ 500	$ 500
Series E convertible preferred stock issued to retire demand promissory note, Shares		556
Series E convertible preferred stock deemed dividend from beneficial conversion feature				$ 376	$ (376)
Series D convertible preferred stock deemed dividend from beneficial conversion feature		$ 330			(330)
Series D convertible preferred stock reclassified to stockholders' equity (deficit)	$ 839	$ 839
Series D convertible preferred stock reclassified to stockholders' equity (deficit), Shares		1,299
Series E convertible preferred stock dividend accrued at period end	(65)				$ (65)
Common stock issued for services	663			663
Common stock issued for services, Shares			50,971
Stock-based compensation expense	1,302			1,302
Net loss	(27,277)				$ (27,277)
Ending Balance at Dec. 31, 2014	(4,071)	$ 5,220	$ 6	$ 45,886	$ (55,183)
Ending Balance, Shares at Dec. 31, 2014		755,799	5,614,605
Sale of Series E convertible preferred stock	4,725	$ 4,725
Sale of Series E convertible preferred stock, Shares		5,250
Sale of Series G convertible preferred stock	6,950	$ 6,950
Sale of Series G convertible preferred stock, Shares		1,622
Proceeds from issuance of common stock	2,883			$ 2,883
Proceeds from issuance of common stock, Shares			273,003
Common stock issued for acquisition of Diogenix	$ 7,951		$ 1	7,950
Common stock issued for acquisition of Diogenix, Shares			662,526
Beneficial conversion feature of Series E convertible preferred stock adjustment due to rice reset from $7.50 to $4.50				2,835	$ (2,835)
Deemed dividends related to immediate accretion of beneficial conversion feature of Series E convertible preferred stock				490	$ (490)
Beneficial conversion feature of Series H convertible preferred stock	$ 1,260			$ 1,260
Deemed dividends related to immediate accretion of beneficial conversion feature of Series H convertible preferred stock	(1,260)				$ (1,260)
Deemed dividend on conversion of Series H convertible preferred stock to common stock	(1,301)				(1,301)
Deemed dividend related to accretion of redemption value of Series H convertible preferred stock	(2,363)				$ (2,363)
Common stock issued for note conversion	1,659		$ 3	$ 1,656
Common stock issued for note conversion, Shares			3,415,574
Common Stock issued for Series D convertible preferred stock quarterly dividend	60			60
Common Stock issued for Series D convertible preferred stock quarterly dividend, Shares			30,349
Common Stock issued for Series E convertible preferred stock quarterly dividend	1,033		$ 1	1,032
Common Stock issued for Series E convertible preferred stock quarterly dividend, Shares			1,003,433
Common stock issued for Series G convertible preferred stock quarterly dividend	2,087		$ 1	2,086
Common stock issued for Series G convertible preferred stock quarterly dividend, Shares			1,452,400
Common stock issued for Series H convertible preferred stock quarterly dividend	213		$ 1	$ 212
Common stock issued for Series H convertible preferred stock quarterly dividend, Shares			555,163
Note payable converted to Series E convertible preferred stock	$ 689	$ 689
Note payable converted to Series E convertible preferred stock, Shares		766
Cancellation of Series G
Cancellation of Series G, Shares			(212,087)
Legal fees related to stock financing	$ (293)			$ (293)
Common stock issued in conversion of Series D convertible preferred stock		$ (1,169)		1,169
Common stock issued in conversion of Series D convertible preferred stock, Shares		(1,299)	288,740
Common stock issued in conversion of Series E convertible preferred stock		$ (700)	$ 1	699
Common stock issued in conversion of Series E convertible preferred stock, Shares		(750)	1,501,112
Common stock issued in conversion of Series G convertible preferred stock		$ (1,810)		1,810
Common stock issued in conversion of Series G convertible preferred stock, Shares		(1,622)	201,112
Purchase of Series G convertible preferred stock, net of conversion portion	$ (4,750)	$ (5,140)		390
Common stock issued in conversion of Series H convertible preferred stock	1,772		$ 6	1,766
Common stock issued in conversion of Series H convertible preferred stock, Shares			5,854,804
Common stock issued as fee for debt financing arrangement	116			$ 116
Common stock issued as fee for debt financing arrangement, Shares			10,200
Series D dividend accrued	(34)				$ (34)
Series E dividend accrued	(1,261)				(1,261)
Series G dividend accrued	2,087				(2,087)
Series H dividend accrued	213				$ (213)
Common stock issued for services	691		$ 1	$ 690
Common stock issued for services, Shares			526,388
Nerverda Warrant Liability	600			600
Stock-based compensation expense	1,470			$ 1,470
Fractional shares issued on reverse split
Fractional shares issued on reverse split, Shares			31
Net loss	(25,214)				$ (25,214)
Ending Balance at Dec. 31, 2015	$ (8,688)	$ 8,765	$ 21	$ 74,767	$ (92,241)
Ending Balance, Shares at Dec. 31, 2015		759,766	21,177,353

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)
Debt conversion, converted instrument, Rate	8.00%
Series E Convertible Preferred Stock [Member]
Payments of stock issuance costs	$ 43

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (25,214)	$ (27,277)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	80	35
Amortization of debt discount	1,298	582
Amortization of deferred financing fees	182	223
Amortization of intangible assets	96	$ 118
Research and development licenses and patent acquired, expensed	5,401
Common stock issued for services	$ 691	$ 663
Common stock issued to acquire in-process research and development		$ 3,000
Convertible notes issued for services	$ 50
Write-off of clinical material		$ 500
Impairment of investment		50
Loss on common stock issuance		$ 260
Loss on issuance of senior secured convertible promissory notes	$ 1,645
Loss on warrant issuance		$ 3,867
Loss on extinguishment of convertible debt	$ 1,296	1,250
Non-cash interest expense related to demand promissory note, warrants and derivative	216	52
Change in fair value of warrants and derivative liability	(4,105)	$ (317)
Change in fair value of share-settled debt	246
Change in fair value of earn-out liability	(917)
Stock-based compensation expense	1,470	$ 1,302
Changes in assets and liabilities:
Deferred financing fees	(151)
Prepaid expenses and other current assets	(152)	$ (92)
Accounts payable and accrued expenses	1,469	4,645
Related party liabilities and accrued interest	5	3
Accrued interest	380	(195)
Net cash used in operating activities	$ (16,014)	(11,331)
Cash flows from investing activities
Restricted cash		$ (204)
Acquisition of DioGenix, Inc, net of non-cash portion	$ (900)
Investment		$ (50)
Purchase of research and development patent	$ (4,000)
Acquisition of property and equipment	$ (10)	$ (181)
Acquisition other assets		(1,100)
Net cash used in investing activities	$ (4,910)	(1,535)
Cash flows from financing activities
Proceeds from notes payable	4,605	$ 500
Proceeds from senior secured convertible promissory notes	2,850
Proceeds from share-settled debt	225
Purchase of Series G convertible preferred stock	(4,750)
Repayment of promissory notes	(105)	$ (9)
Legal fees related to stock financing	(293)	(43)
Proceeds from issuance of common stock	$ 2,883	3,074
Proceeds from exercise of warrants		4,975
Net cash provided by financing activities	$ 20,886	12,047
Net decrease in cash and cash equivalents	(38)	(819)
Cash and cash equivalents, beginning of the year	214	1,033
Cash and cash equivalents, end of period	176	$ 214
Acquisition of DioGenix, Inc
Prepaid expenses and other current assets	(13)
Property and equipment, net	(40)
Intangible assets	(1,961)
goodwill	(7,967)
Earn-out liability	917
Deferred tax liability	1,113
Common stock issued for acquisition of Diogenix	$ 7,951
8% senior convertible debentures and accrued interest, net of unamortized debt discount and associated derivative liability converted to common stock		$ 7,091
Debt discount associated with convertible promissory note - derivative liability	$ 3,720
Issuance of warrants at fair value related to convertible debt	3,096
Warrant liability limitations adjustment	1,045
Fair Value of common stock warrant issued with Series H convertible preferred stock	2,534
Beneficial conversion feature of Series H convertible preferred stock	1,260
Deemed dividends related to immediate accretion of beneficial conversion feature of Series H convertible preferred stock	1,260
Deemed dividend on conversion of Series H convertible preferred stock to common stock	1,301
Deemed dividend related to accretion of redemption value of Series H convertible preferred stock	2,363
Deemed dividends related to immediate accretion of beneficial conversion feature of Series E convertible preferred stock	490
Beneficial conversion feature of Series E convertible preferred stock adjustment due to rice reset from $7.50 to $4.50	2,835
Common stock issued as fee for debt financing arrangement	116
Common stock issued for Series D convertible preferred stock quarterly dividend	60
Common stock issued for Series E convertible preferred stock quarterly dividend	1,033
Common stock issued for Series G convertible preferred stock quarterly dividend	2,087
Common stock issued for Series H convertible preferred stock quarterly dividend	213
Common stock issued in conversion of Series D convertible preferred stock	1,169
Common stock issued in conversion of Series E convertible preferred stock	700	$ 104
Common stock issued in conversion of Series G convertible preferred stock	1,810
Common stock issued in conversion of Series H convertible preferred stock	1,772
Common stock issued for note conversion	1,659	$ 130
Series D dividend accrued	34
Series E dividend accrued	1,261	$ 65
Series G dividend accrued	2,087
Series H dividend accrued	$ 213
Common stock issued in consideration of commitment fees for equity financing		516
Common stock issued to acquire intangible assets		354
Common stock issued in settlement of accounts payable		$ 68
Exchange of notes payable for senior secured convertible debt	$ 3,021
Note payable converted to Series E convertible preferred stock	689	$ 500
Series E convertible preferred stock
Cash flows from financing activities
Sale of convertible preferred stock	4,725	$ 3,550
Series G convertible preferred stock
Cash flows from financing activities
Sale of convertible preferred stock	6,950
Series H convertible preferred stock
Cash flows from financing activities
Sale of convertible preferred stock	$ 3,796

General

General	12 Months Ended
	Dec. 31, 2015
General [Abstract]
General	1. General Amarantus Bioscience Holdings, Inc. (”the Company”) is a California based biopharmaceutical company founded in January 2008. The Company owns or have exclusive licenses to various product candidates in the biopharmaceutical and diagnostic areas of the healthcare industry. The Company is developing a diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company’s business model is to develop product candidates through various de-risking milestones that will be accretive to shareholder value, and will strategically partner with pharmaceutical companies, diagnostic companies and/or other stakeholders in order to more efficiently achieve regulatory approval and commercialization. The Company has three operating divisions: the diagnostics division; the therapeutics division; and the drug discovery division. Reverse Stock Split On May 2, 2015, the Company’s Board of Directors and stockholders approved a 1-for-150 reverse stock split of the Company’s authorized, issued and outstanding common stock. The reverse stock split became effective on June 10, 2015. Upon the effectiveness of the reverse stock split, (i) every one hundred and fifty shares of outstanding common stock was combined into one share of common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased, and (iv) the conversion ratio for each share of preferred stock outstanding was proportionately reduced. Unless otherwise indicated, all of the share numbers, share prices and exercise prices in these consolidated financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-150 reverse stock split.

Liquidity and Going Concern

Liquidity and Going Concern	12 Months Ended
	Dec. 31, 2015
Liquidity and Going Concern [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Historically, we have incurred net losses and negative cash flows from operations. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. Historically, the Company has incurred net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Principles of Consolidation Reclassification Use of Estimates Certain Significant Risks and Uncertainties Concentration of Credit Risk Cash and Cash Equivalents Property and Equipment Equipment 3 years Computer equipment 2 years Furniture and fixtures 3 years Accounting for Business Combinations - Contingent consideration assumed in a business combination is remeasured at fair value each reporting period and any change in the fair value from either the passage of time or events occurring after the acquisition date, is recorded in results from operations. The results of operations are included from the acquisition date in the financial statements for all businesses acquired. Goodwill and Other Identifiable Intangibles - The Company estimates the fair value of the reporting unit using a market approach in combination with a discounted operating cash flow approach. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. An adjustment to goodwill will be recorded for any goodwill that is determined to be impaired. The Company tests goodwill for impairment at least annually in conjunction with the preparation of its annual business plan, or more frequently if events or circumstances indicate it might be impaired. For reporting units with zero or negative carrying amounts, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. In determining whether it is more likely than not that goodwill impairment exists, an entity should consider whether there are any adverse qualitative factors indicating that impairment may exist. As of December 31, 2015, the Company performed a quantitative goodwill impairment test and determined that goodwill was not impaired. Impairment of Long-Lived Assets Research and Development Expenditures Fair Value of Financial Instruments Fair value is defined under the standard as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The standard also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value: ● Level 1 ● Level 2 ● Level 3 Stock-Based Compensation Grant-date fair value is determined using the Black-Scholes option pricing model, which requires the use of the following assumptions: Expected Term Expected Volatility Risk-Free Interest Rate Expected Dividend Forfeiture Rate The fair value of stock options granted to nonemployees is recognized over the period in which the related services are received. Debt Extinguishment - Share-settled Debt – Sequencing As of October 2015, the Company adopted a sequencing policy whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. Preferred Stock Convertible Financial Instruments When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. Common Stock Purchase Warrants and Derivative Financial Instruments - Common stock purchase warrants and other derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions that do not qualify for the scope exception are classified as equity or liabilities. The Company assesses classification of its common stock purchase warrants and other derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required. Debt Discounts - Income Taxes In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. Interest and penalties related to uncertain tax positions are recorded in the provision for income tax expense on the consolidated statements of operations. Net Loss Per Common Shareholder - Segments Subsequent Events Adoption of Recent Accounting Pronouncements In August 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-15, “Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the treatment of debt issuance costs from line-of-credit arrangements after the adoption of ASU No. 2015-03, “Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. In particular, ASU No. 2015-15 clarifies that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to a line-of-credit arrangement as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of such arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted ASU No. 2015-15 and its adoption did not have a material impact on the consolidated financial statements. Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “ Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, “ Presentation of Financial Statements — Going Concern (Subtopic 205-40) — Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” In November 2014, the FASB issued ASU No. 2014-16, Derivatives and Hedging ("ASU 2014-16"), which clarifies how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The amendments in this Update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption, including adoption in an interim period, is permitted. The Update does not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The Company will adopt ASU 2014-16 on January 1, 2016 and does not believe the adoption of this ASU to have a material impact on the combined and consolidated financial statements. ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840)

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Business Combinations	4. Business Combinations Acquisition of Diogenix, Inc. On January 8, 2015, the Company acquired DioGenix, which owns a pipeline of diagnostic tests focused on immune-mediated neurological diseases, such as multiple sclerosis (MS). Its lead product, MSPrecise, can significantly expand a physician's ability to diagnose patients that exhibit unclear neurological dysfunction. Consideration paid included 662,526 shares of Company stock valued at $12.00 per share and $0.9 million in cash for a total consideration of $8.9 million. In addition, the agreement provides for a contingent payment amount up to $2.0 million in cash and common stock of the Company should the acquired company achieve certain milestones related to results of clinical testing and future revenue from products in development. The fair value of the contingent consideration was estimated by applying the income approach. That measure is based on significant inputs that are not observable in the market (Level 3 inputs). Key assumptions include the discount rate of 30.4% and probability-adjusted potential outcomes. Following an acquisition, there is a period of not more than twelve months from the closing date of the acquisition to finalize the acquisition date fair values of assets acquired and liabilities assumed, including valuations of identifiable intangible assets and property and equipment. The purchase price allocation was finalized on December 31, 2015. The determination of fair values of acquired intangible assets and property and equipment involves a variety of assumptions, including estimates associated with remaining useful lives. The following unaudited supplemental pro forma information presents the financial results as if the Merger had occurred on January 1, 2014. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2014, nor is it indicative of any future results (amount in thousands): For the year end December 31, 2014 (Unaudited) Net Sales $ - Operating Expenses 23,335 Loss from operations (23,335 ) Total other expenses (6,378 ) Net Loss (29,713 ) Basic and diluted net loss per common share $ (0.04 ) The allocation of the purchase price to the Company’s balance sheet is shown below (amount in thousands): January 8, 2015 Intangibles - Acquisition Diogenix (IPR&D) $ 2,861 Prepaid expenses and other current assets 13 Property and equipment, net 40 Goodwill 7,967 Total assets 10,881 Earn-out liability (917 ) Deferred tax liability (1,113 ) Net assets acquired $ 8,851 Goodwill represents expected synergies resulting from the combination of the entities and other intangible assets that do not qualify for separate recognition, while IPR&D assets represent ongoing projects obtained through the acquisition. The transaction was accounted for using the acquisition method. Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed including the related deferred tax liability. Goodwill is not deductible for tax purposes.

Research and Development Licens

Research and Development Licenses and Patent Acquired	12 Months Ended
	Dec. 31, 2015
Research and Development Licenses and Patent Acquired [Abstract]
Research and Development Licenses and Patent Acquired	5. Research and Development Licenses and Patent Acquired The following table summarizes the Company’s intangible assets (amount in thousands): As of December 31, 2015 2014 Intangibles - Acquisition Diogenix (IPR&D) $ 2,861 $ - Licenses - 1,497 Total intangible assets $ 2,861 $ 1,497 Acquisition of Diogenix The Company tested its intangible assets for impairment during the fourth quarter of 2015 and determined that its intangible assets were not impaired. Asset Acquired in Research and Development On July 8, 2015, the Company exercised its previously disclosed option to acquire Intellectual property rights on the Engineered Skin Substitute for $4.0 million. Pursuant to the Agreement, the Company will be required to pay up to $5.0 million in aggregate milestone payments upon the achievement of certain regulatory milestones, none of which have currently been met. Cost incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached commercial feasibility and has no alternative future use. Such licenses purchased by the Company require substantial completion of research and development, regulatory and marketing approval efforts in order to reach commercial feasibility and has no alternative future use. Accordingly, the total purchase price of $4.0 million Licenses The Company concluded that there is no further alternative future use associated with the licensed assets and as such they were expensed to the statement of operations as research and development cost.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable $1.0 Million Notes Payable Securities Purchas Agreement On July 9, 2015, the Company entered into a Securities Purchase Agreement with four investors to purchase an aggregate of $1.0 million in principal amount of 12% Promissory Notes (the “Notes Payable”) due July 9, 2016. One Note Payable Investor, with $0.6 million in Notes Payable has the right to exchange the Notes Payable for 12% Senior Secured Convertible Notes at any time. $0.6 million Conversion Feature The conversion feature of the $0.6 million note was treated as an embedded conversion feature and bifurcated for financial statement purposes, as the terms were not indexed to the Company’s stock. The Notes Payable are currently in default. Other miscellaneous debt agreements During the years ended December 31, 2015, the Company entered into multiple note agreement (the “Notes”) with multiple investors for an aggregate of $105,000 in principal. The notes were fully paid back as of December 31, 2015.

Senior Secured Convertible Prom

Senior Secured Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Senior Secured Convertible Promissory Notes	7. Senior Secured Convertible Promissory Notes The following is a summary of outstanding senior secured convertible notes as of December 31, 2015 (amount in thousands): Stated Remaining Issue Date Maturity Date Interest Rate Conversion Terms Face Value Debt Discount Carrying Value Delafield Investments Ltd 9/30/2015 9/29/2016 12 % $ 0.43 $ 3,056 $ (2,286 ) $ 770 Dominion Capital LLC 9/30/2015 9/29/2016 12 % $ 0.43 2,096 (1,568 ) 528 US 1000 LLC 12/07/2015 12/6/2016 12 % N/A 100 - 100 Ending balance as of December 31, 2015 $ 5,252 $ (3,854 ) $ 1,398 12% Senior Secured Convertible Promissory Note and Warrants Delafield Notes On September 30, 2015, the Company entered into a Securities Purchase Agreement (the “Notes SPA”) with an institutional investor for the sale of an aggregate principal amount $3.1 million (including 10% OID) 12% Senior Secured Convertible Promissory Notes due September 29, 2016 (the “Delafield Notes”) and a warrant to purchase 1,299,000 shares of common stock. The proceeds to the Company from the sale was $2.7 million. Delafield Warrants The warrants are exercisable after March 31, 2016 and terminate on the five-year anniversary of that date. The warrants had an initial exercise price of $2.00 per share. The warrants have an aggregate exercise provision that upon reset the amount of warrant coverage increases proportionally to the decrease in exercise price. The terms of the warrants had reset provisions that precluded their inclusion as equity and was recorded as a warrant liability on the balance sheet. As of December 31, 2015, the debt discount associated with Delafield Notes was $2.3 million, and expected to be amortized in 9 months. Dominion Notes On September 30, 2015, the Company entered into an exchange agreement with an institutional investor pursuant to which the Company exchanged $3.0 million (including OID and make-whole) Notes Payable previously issued in 2015, which included principal and accrued interest for a $3.0 million Senior Secured Convertible Promissory Note (“Dominion Note”) and a common stock purchase warrant to purchase 1,299,000 with a $2.00 exercise price. The warrants have an aggregate exercise provision that upon reset the amount of warrant coverage increases proportionally to the decrease in exercise price. The terms of the warrants had reset provisions that precluded their inclusion as equity and was recorded as a warrant liability on the balance sheet. Conversion of Dominion Notes During the quarter ended December 31, 2015, the Company entered into a conversion agreement with the investor to covert an aggregate amount of $0.9 million of the Dominion Notes to 3,415,574 shares of common stock. The Company recognized a loss on extinguishment of $1.3 million from the conversion of convertible debt with a bifurcated conversion option, which included the write-off of $0.4 million of derivative liability, $0.9 million in debt discount and fair value of the common shares issued of $1.7 million. As of December 31, 2015, the debt discount associated with Dominion Notes was $1.6 million, and expected to be amortized in 9 months. Senior Secured Convertible Promissory Notes - Interest Terms The principal amount of the Dominion Notes and Delafield Notes (“Senior Secured Notes”) shall accrue interest at a rate equal to 12% per annum, payable on the Maturity Date in cash, or, at the Company’s option, in common stock or a combination thereof. At any time upon five (5) days written notice to the Investor, the Company may prepay any portion of the principal amount of the Senior Secured Notes and any accrued and unpaid interest at an amount equal to 120% of the then outstanding principal amount of the Senior Secured Notes and accrued interest or 130% if a Qualified Financing (as defined in the Senior Secured Notes) has occurred. Senior Secured Convertible Promissory Notes - Security interest In connection with the issuance of the Senior Secured Notes, the Company granted a security interest in all of its assets to the note holders. Senior Secured Convertible Promissory Notes - Events of Default The Senior Secured Notes contain certain customary Events of Default (including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, including the transaction documents relating to the PP Offering, changes in control of the Company, filing of bankruptcy and the entering or filing of certain monetary judgments against the Company). Upon the occurrence of any such Event of Default the outstanding principal amount of the Senior Secured Notes, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become, at the Investor’s election, immediately due and payable in cash. Upon any Event of Default that results in acceleration of the Senior Secured Notes, the interest rate on the Senior Secured Notes shall accrue at an interest rate equal to the lesser of 24% per annum or the maximum rate permitted under applicable law. The Company is currently in default with all Senior Secured Notes. Senior Secured Convertible Promissory Notes - Conversion Features At any time after the issuance date of the Senior Secured Notes until all amounts due have been paid in full, the Senior Secured Note shall be convertible, in whole or in part, into shares of common stock at the option of the holder, at any time and from time to time. The conversion price in effect on any conversion date shall be equal to the lowest of (i) $2.50, (ii) 75% of the lowest daily VWAP in the fifteen (15) trading days prior to the conversion date, or (iii) (A) if a Public Offering (as defined in the Senior Secured Note) that is not a Qualified Public Offering (as defined in the Senior Secured Note) has occurred, 75% or (B) if a Qualified Public Offering has occurred, 80% of the lowest of the (x) per share price of shares of common stock, and (y) the lowest conversion price, exercise price or exchange price of any common stock equivalents, that are sold or issued to the public in the Public Offering or the Qualified Public Offering, respectively. The conversion features of the notes were bifurcated from the host instrument as its conversion terms were not indexed to the company’s own stock. In addition, the warrants associated with the debt instruments were also treated as a free standing derivative liability. The total fair value of the embedded conversion feature and the warrants exceeded the net proceeds received and resulted in a loss on issuance of $1,045. Other Convertible Notes Payable On July 1, 2015, the Company entered into a Securities Purchase Agreement with an institutional investor (the “Investor”) pursuant to which such Investor purchased an aggregate of $0.6 million in principal amount of 12% Convertible Promissory Notes (the “Notes”) due April 2, 2016. This note was shortly thereafter converted into 766 shares of Series E Convertible Preferred Stock with a 10% OID discount. On December 7, 2015, the Company entered into a Securities Purchase Agreement with an institutional investor (the “Investor”) pursuant to which such Investor purchased an aggregate of $100,000 in principal amount of Convertible Promissory Notes.

Share-settled Debt

Share-settled Debt	12 Months Ended
	Dec. 31, 2015
Share-settled Debt [Abstract]
Share-settled Debt	8. Share-settled Debt On August 27, 2015, the Company entered into a Securities Purchase Agreement with an institutional investor pursuant to which such Investor purchased an aggregate of $75,000 in principal amount of 20% Convertible Promissory Notes due February 24, 2016. The conversion price is 55% of the lowest VWAP of the prior 5 trading days. On October 14, 2015, the Company entered into a Securities Purchase Agreement with an institutional investor pursuant to which such Investor purchased an aggregate of $150,000 in principal amount of 15% Promissory Notes due November 4, 2016. The conversion price is 55% of the lowest VWAP of the prior 5 trading days. On November 20, 2015, the Company issued a convertible promissory note in principal amount of $50,000 to a vendor in exchange for its services. The conversion price is 50% of the average of the lowest 3 closing prices for 10 trading days prior to but not including the conversion date These three convertible notes (the “Notes”) settle by providing the holder with a variable number of the Company’s shares with an aggregate fair value determined by reference to the debt principal outstanding. Because the value that the holder receives at settlement does not vary with the value of the Company’s equity shares, the settlement provision is not considered a conversion option for financial accounting purposes. Rather, these Notes are recognized as share-settled debt at fair value. During 2015, the Company recorded $0.2 million change in fair value of the Notes. The share-settled debt is currently in default.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Measurements [Abstract]
Fair Value Measurements	9. Fair Value Measurements The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2015 by level within the fair value hierarchy, are as follows: Fair value measured at December 31, 2015 Fair value at Quoted Significant other observable Significant unobservable December 31, markets inputs inputs 2015 (Level 1) (Level 2) (Level 3) Derivative liability $ - $ - $ 2,073 $ 2,073 Warrant liability - - 3,025 3,025 Share-settled debt - - 521 521 Total fair value $ - $ - $ 5,619 $ 5,619 There were no transfers between Level 1, 2 or 3 during the years ended December 31, 2015 and 2014. The following table presents additional information about Level 3 liabilities measured at fair value. Both observable and unobservable inputs may be used to determine the fair value of positions that the Company has classified within the Level 3 category. As a result, the unrealized gains and losses for assets and liabilities within the Level 3 category may include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs. Changes in Level 3 liabilities measured at fair value for the period ended December 31, 2015 and December 31, 2014 were as follows (dollars in thousands): Warrant Liability Earn-out Embedded Conversion Feature Share-settled Debt Total January 1, 2014 $ - $ 5,859 $ - $ 5,859 Conversion of 8% senior convertible debentures to common stock - (5,542 ) - (5,542 ) Change in fair value - (317 ) - (317 ) December 31, 2014 - - - - Issuance of convertible notes - 3,936 - 3,936 Issuance of share-settled debt - - 275 275 Addition of earn-out liability 917 917 Issuance of warrants 5,631 - - 5,631 Conversion of 8% senior convertible debentures to common stock - (363 ) - (363 ) Change in fair value (2,606 ) (917 ) (1,500 ) 246 (4,777 ) December 31, 2015 $ 3,025 - $ 2,073 $ 521 $ 5,619 The fair value of contingent earn-out liability was determined using discounted cash flow models for multiple revenue scenarios. To calculate the fair value of the contingent liability, the probability of the discounted fair value of each scenario was weighted. As of December 31, 2015, the Company determined that the fair value of the earn-out liability was $0. The Company’s warrant liabilities, derivative liabilities and share-settled debt are measured at fair value using the Monte Carlo simulation valuation methodology. A summary of weighted average (in aggregate) about significant unobservable inputs (Level 3 inputs) used in measuring the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy for the years ended December 31, 2015 is as follows: As of December 31, 2015 Warrant Liability Derivative Liability Share-settled Debt Contractual life (years) 4.8 0.8 0.4 Annualized volatility* 71 % 70 % 70 % Conversion price $ 2.00 $ 2.50 $ 0.30 Expected dividends 0 % 0 % 0 % Risk-free investment rate 1.7 % 0.6 % 0.6 % * The Company uses comparable companies within the same industry to derive at the 70% annualized volatility.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2015
Net Loss Per Share [Abstract]
NET LOSS PER SHARE	10. Net Loss per Share The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders for the periods indicated (amount in thousands): As of December 31, 2015 2014 Numerator: Net loss $ (25,214 ) $ (27,277 ) Preferred stock dividend (3,595 ) (875 ) Deemed dividends on convertible preferred stock (8,249 ) - Net loss attributable to common stockholders $ (37,058 ) $ (28,152 ) Denominator: Weighted Average Common stock outstanding 8,878,000 4,926,000 Basic and diluted net loss per share $ (4.17 ) $ (5.71 ) Potentially dilutive securities consist of: As of December 31, 2015 2014 Outstanding common stock options 308,000 201,000 Outstanding preferred stock option 829,000 829,000 Common Stock Purchase Warrants 12,810,000 311,000 Related party liability 401,000 20,000 Convertible senior secured promissory notes and accrued interest 12,382,000 - Convertible preferred stock Series C 5,000 5,000 Convertible preferred stock Series D - 289,000 Convertible preferred stock Series E 1,302,000 375,000 Convertible preferred stock Series H 6,534,000 - Potentially dilutive securities 35,021,000 2,030,000 All of the listed dilutive securities are excluded from the computation of fully diluted loss per share as they are antidilutive.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	11. Commitments and Contingencies Commitments: Sponsored Research Arrangements: The Company entered into a number of sponsored research agreements during 2015, primarily, which require us to make future payments as follows (amount in thousands): 2016 $ 150 Total $ 150 Lease Arrangements The Company leases its main office facility and laboratory space in two separate locations in San Francisco, California. Office space in San Francisco is leased through November 2016 and provides for a monthly rental payment of approximately $12,600, plus operating expenses, subject to annual adjustment, of approximately $9,000 per month. The other facility lease is on a month-to-month basis. Future non-cancellable minimum lease payments are (amount in thousands): 2016 $ 139 Total $ 139 Rent expense for the years ended December 31, 2015 and 2014 was $407,000 and $150,000, respectively.

Temporary Equity

Temporary Equity	12 Months Ended
	Dec. 31, 2015
Temporary Equity [Abstract]
Temporary Equity	12. Temporary Equity The following table summarizes the Company’s Series H Preferred Stock activities for the year ended December 31, 2015 (amount in thousand): Series H convertible Shares Value Total temporary equity as of December 31, 2014 - $ - Proceeds from sale of Series H preferred stock, net of issuance costs of $0.4 million 4,588 3,796 Beneficial conversion feature of Series H convertible preferred stock - (1,260 ) Deemed dividends related to immediate accretion of beneficial conversion feature of Series H convertible preferred stock - 1,260 Fair Value of common stock warrant issued with Series H convertible preferred stock - (2,534 ) Common stock issued in conversion of Series H convertible preferred stock (1,772 ) (1,772 ) Deemed dividend on conversion of Series H convertible preferred stock to common stock - 1,301 Deemed dividend related to accretion of redemption value - 2,363 Total temporary equity as of December 31, 2015 2,816 $ 3,154 Securities Purchase Agreement In September 2015, the Company entered into a Securities Purchase Agreement (the “Series H SPA”) with an institutional investor for the sale of 3,056 (including 10% OID) shares of the Company’s 12% Series H Preferred Stock (the “Series H Preferred Stock”) and a warrant to purchase 1,299,000 shares of common stock (the “RD Warrant” and together with the Series H Preferred Stock, the “Securities”) in a registered direct offering (the “RD Offering”), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $2.4 million, net of $0.3 million of legal fees. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder. The proceeds of the raise was used to buyout the holders of the Series G. A minimal amount was remaining and was included as a dividend. The RD Warrant is exercisable at any time on or after the earlier to occur of (i) all shares of common stock underlying the RD Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from September 30, 2015 (the earlier to occur of (i) and (ii), the “Initial Exercise Date”) and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share. The warrant had price protection terms that precluded an equity classification, as such $1,548 was recorded as a derivative liability and recorded as net of proceeds. 4 th During the quarter ended December 31, 2015, the Company sold additional 1,532 (including 10% OID) shares of the Company’s Series H Preferred Stock and a warrant to purchase 650,896 shares of common stock for gross proceeds of $1.4 million. During the year ended December 31, 2015, the Company recorded a deemed dividend of $0.9 million related to the beneficial conversion feature with the issuance of the Series H Convertible Preferred stock. During the year ended December 31, 2015, 1,772 shares of Series H Preferred were converted to common stock. Upon conversion the Company recorded an additional deemed dividend of $1.6 million. Temporary equity The instrument is being classified as temporary equity because it has redemption features outside of the Company’s control upon certain triggering events. If the Company fails to provide at all times the Registration Statement or usable prospectus that permits the Company to issue the Conversion Shares or which allows the Holder to sell the Conversion Shares pursuant thereto), is considered outside of the Company’s control. Redemption value The Company is carrying the Series H at its maximum redemption amount at December 31, 2015 as the security is not currently redeemable, but is redeemable subsequent to December 31, 2015. The Company recognized the change immediately as if the redemption was to occur as of December 31, 2015. The current redemption amount is $3.1 million as of December 31, 2015

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity [Abstract]
Stockholders' Equity	13. Stockholders’ Equity Preferred Stock Series D Convertible Preferred Stock On June 30, 2014, with the approval of the holder of the Company’s Series D Preferred Stock, the Company filed an amendment to the Certificate of Designation of the Series D Preferred Stock to remove the feature by which stockholder could require redemption of the stock at cost. Accordingly, since the Series D Preferred Stock now contains mainly equity-like features, the Company changed the classification of the stock on its balance sheet from temporary equity to permanent equity within stockholders’ equity (deficit). The Series D securities were issued at 10% discount and contain a beneficial conversion feature. The beneficial conversion feature has been accreted, resulting in a deemed dividend reflected in the December 31, 2014 Consolidated Statements of Stockholders’ Equity (Deficit). The value of the original issue discount is $130 and the beneficial conversion feature is $321. During the first quarter of 2015, 549 shares of Series D preferred stock were converted to 122,073 common shares, and 2,045 shares of common stock were issued as a dividend due upon conversion. Also, 7,819 shares of common stock were issued as a quarterly dividend. During the second quarter of 2015, 400 shares of Series D preferred stock were converted to 88,889 common shares. Also, 3,620 shares of common stock were issued as a quarterly dividend. During the third quarter of 2015, 350 shares of Series D preferred stock were converted into 77,778 common shares. Series E Convertible Preferred Stock On November 7, 2014, the Company entered into securities purchase agreements pursuant to which the Company issued 4,500 shares of Series E Convertible Preferred Stock (”Series E Preferred Stock”) which has a stated value of $1,000 and pays quarterly 12% cumulative dividends per annum. Dividends are payable by the Company in cash or at the Company’s option, in shares of common stock if certain conditions are met. These conditions include availability of funds or no occurrence of a triggering event. Triggering events include change of control, bankruptcy, junior security redemptions, the Company’s common stock shall fail to be listed or quoted on a Trading Market for more than five Trading Days. As of December 31, 2015 no triggering event has occurred. Series E Make-whole dividend rights Holders of Series E shares are entitled to three years of dividends from the date of issuance net of dividends already accrued. Each share of Series E Preferred Stock is convertible into shares of common stock by dividing the stated value per share by the then effective conversion price. The conversion price for the Series E is $12.00 per share, subject to adjustment under certain conditions, but in no event prior to six months from issuance. Series E voting rights Series E Preferred stockholders have the right to vote on all matters submitted to the Company’s shareholders and the Series E Preferred Stock are entitled to such number of votes on an as-converted basis. Series E Preferred Stock also has a liquidation preference equal to the stated value and accrued and unpaid dividends. Sales of Series E During 2014, the Company sold 3,944 shares of Series E Preferred Stock for proceeds of $3.5 million, net of issuance costs of $43,000. The Company also issued 556 shares of Series E Preferred Stock to retire a $0.5 million demand promissory note. The Series E shares were issued at 10% discount and contain a beneficial conversion feature. The beneficial conversion feature has been accreted, resulting in a deemed dividend reflected in the December 31, 2014 Consolidated Statements of Stockholders’ Equity (Deficit). The value of the original issue discount is $450 and the beneficial conversion feature is $376. Through December 31 2015, the Company has sold an additional 5,250 shares of Series E convertible preferred stock for gross proceeds of $4.7 million. Senior Secured Notes Conversion into Series E During the year ended December 31, 2015, the Company converted $0.7 million senior secured notes to 766 shares of Series E Preferred Stock. Series E Conversions into common stock Through December 31 2015, the Company converted 750 Series E shares to 1,501,112 common shares, and 1,003,433 shares of common stock were issued as a dividend. Conversion Price On July 9, 2015, the Company filed an amended and restated Certificate of Designation of its Series E Preferred Stock (the “Amendment”). The Amendment changed the conversion price for the Series E Preferred to $7.50, subject to adjustment commencing on January 8, 2016 (the “Conversion Price”). After January 8, 2016, in the event that Preferred Stock is outstanding, a Holder delivers a Notice of Conversion within 5 Trading Days following a period that the average of 3 consecutive VWAPs is less than $9.00 (subject to adjustment for reverse and forward stock splits and the like)(“Trigger Period”), the Conversion Price shall be thereafter reduced, and only reduced, to equal the lesser of the then Conversion Price (as previously adjusted) and 65% of the average of the lowest 2 consecutive VWAPs out of the prior 10 consecutive Trading Days prior to the delivery of such Conversion Notice. Such adjustment may occur on multiple occasions during any Trigger Period and shall permanently reduce, and never increase, the Conversion Price. Notwithstanding the foregoing if the common stock of the Company is listed on NASDAQ and the price is $18.00 at the time of listing and for 10 consecutive Trading Days after such listing (subject to adjustment for reverse and forward stock splits and the like), then the adjustment of the Conversion Price above shall be 80% instead of 65% of the average of the lowest 2 consecutive VWAPs out of the prior 10 consecutive Trading Days. Liquidation preference The liquidation preference for Series E convertible preferred stock was $12.5 million as of December 31, 2015. Series G Preferred Stock Issuance In the second quarter of 2015, the Company issued 1,087 shares of Series G Preferred stock for gross proceeds of $5.0 million, which was net of 8% original issue discount. On July 10, 2015, the Company entered into an Amended and Restated Securities Purchase Agreement (the “Series G SPA”) with an institutional investor for the sale of 435 shares of the Company’s Series G Preferred Stock and an additional 100 shares of Series G Preferred Stock as a fee (collectively, the “Shares”) in a registered direct offering (the “Offering”), subject to customary closing conditions. The gross proceeds to the Company from the registered direct offering were $2.0 million. Closing conditions were met on July 10, 2015 and the transaction was closed on July 13, 2015. The Series G Preferred Stock has a fixed conversion price of $9.00. Repurchase Agreement On September 25, 2015, the Company entered into a repurchase agreement (the “Repurchase Agreement”) with the holder of all of the Company’s issued and outstanding Series G Preferred Stock (the “Series G Holder”) pursuant to which the Company repurchased the remaining Series G Preferred Stock and all shares of common stock held by the Series G Holder for an aggregate purchase price of $4,750. As of October 1, 2015, there are no more shares of Series G Preferred Stock issued and outstanding. Conversions 1,622 shares of Series G converted through December 31, 2015 into 201,112 of common shares. In addition, the holders upon conversion received a conversion premium amount based on an agreed upon dividend rate which ranged 13-24% and six years from the date of notice of exercise. In aggregate a conversion premium amount of $1.9 million was due the holders. The conversion premium amount was converted into common stock based upon an agreed upon discount to the common stock price, which ranged between $0.90 to $3.40. This resulted in additional common stock issued of approximately 1,416,000. Common Stock The Company is authorized to issue 35,000,000 shares of common stock, $0.001 par value. The holders of common stock: (i) have equal rights to dividends from funds legally available therefore, ratably when as and if declared by the Company’s Board of Directors; (ii) are entitled to share ratably in all assets of the Company available for distribution to holders of common stock upon liquidation, dissolution, or winding up of the affairs of the Company; (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions applicable thereto; (iv) are entitled to one non-cumulative vote per share of common stock, on all matters which shareholders may vote on at all meetings of shareholders; and (v) the holders of common stock have no conversion, preemptive or other subscription rights. There is no cumulative voting for the election of directors. Each holder of the Company’s common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. As of December 31, 2015, the Board of Directors had declared no dividends payable to holders of the Company’s common stock. Common stock private placement In March 2014, the Company entered into an equity financing agreement (“LPC Purchase Agreement”) with Lincoln Park Capital Fund LLC (“LPC”) whereby LPC is obligated to purchase up to $20.0 million of the Company’s common stock from time to time over a 30 month period, as directed by the Company and subject to certain requirements, restrictions and limitations. Under the LPC Purchase Agreement, the per share purchase price will be the lesser of the lowest sale price of common stock on the purchase date or the average of the three lowest closing purchase prices during the ten consecutive business days prior to the purchase date. However, LPC is not obligated to purchase shares from the Company on any date that the closing price of the common stock is below $6.00, subject to adjustment upon the occurrence of certain stock related events. The Company may also request that LPC purchase shares under an accelerated purchase notice whereby the per share purchase price will be the lower of (i) 94% of a volume weighted average price calculation as determined under the LPC Purchase Agreement or (ii) the closing price of the common stock on the accelerated purchase date. Concurrently with the execution of the LPC Purchase Agreement, LPC purchased an initial 26,667 shares for gross proceeds of $0.4 million. In consideration for entering into the LPC Purchase Agreement, the Company issued 63,333 shares of common stock to LPC (the ‘Commitment Fee Shares’), 40,000 upon entering into the agreement and 23,333 contingently issuable on a pro rata basis as the Company utilizes the financing arrangement. The agreement will automatically terminate upon the earlier of 30 months (August 2016) or upon full utilization of the purchase commitment. The fair value of the 40,000 Commitment Fee Shares initially issued to LPC was approximately $0.5 million at issue and initially recorded as a deferred funding fee asset. The fee, as well as fair value at issue of subsequent Commitment Fee Shares, has been recognized as additional paid in capital as of December 31, 2014. During the first quarter of 2015 under the Lincoln Park Capital Fund LLC financing arrangement the Company sold 256,305 common shares and issued 3,290 common shares as a commitment fee for a total of $2.8 million. Service Compensation During the year ended December 31, 2015, the Company issued an aggregate of 526,388 shares of common stock to multiple venders as service compensation. The Company recorded $0.7 million service cost based on the fair value of the common stock on the issuance date. Warrants Nervada Warrants On September 30, 2015 the Company issued warrants to purchase 500,000 shares of its common stock in exchange for an existing investor to agree to a lock-up of shares of common stock it held. The warrants are exercisable at $0.01 per share. The Company fair valued the warrant at $0.6 million and recorded a loss on issuance. The inputs included the exercise price of $0.01, contractual term of 5 years, volatility of 250% and risk free rate of 1%. The warrants are not exercisable until September 30, 2016. Common Stock Purchase Warrants The following table summarizes the Company’s warrant activities for the years ended December 31, 2015 and 2014: Weighted Average Number of Weighted Average Remaining Contractual Warrants Exercise Price Term Outstanding as of December 31, 2013 563,689 $ 9.00 1.69 Issued in connection with warrant exchange 300,000 18.00 Exercised (552,777 ) 9.00 Outstanding as of December 31, 2014 310,912 18.00 3.06 Issued in connection with various financings (1) 5,046,705 2.00 Reset Warrants (2) 7,460,353 0.71 Expired and cancellation (8,020 ) 9.00 Outstanding as of December 31, 2015 12,809,950 $ 1.14 4.77 (1) Approximately 4,547,000 warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period. (2) Certain warrants contain aggregate exercise provisions, and upon a reset the exercise price is decreased and the amount of common stock available under the warrant agreement increases. During the 4th quarter a reset occurred decreasing the exercise price from $2.00 to $0.71 and increasing the amount of common stock available to be issued from 4,106,000 to 11,566,000

Stock Option Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2015
Stock Option Plans [Abstract]
Stock Option Plans	14. Stock Option Plans 2008 Stock Plan The Company’s Board of Directors approved the 2008 Stock Plan (the “Plan”). Under the Plan, the Company may grant up to 307,466 shares of incentive stock options, nonqualified stock options, or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years. The following table is a summary of activity under the 2008 Plan: Common stock Weighted Weighted Average Remaining options Average Contractual outstanding Exercise Price Term Balance December 31, 2013 46,275 $ 7.50 8.00 Options granted (weighted-average fair value of $0.08) Employee (1) 83,333 13.50 8.20 Non-employee 22,009 12.00 8.20 Options cancelled (7,643 ) 10.50 Outstanding as of December 31, 2014 143,974 11.50 7.80 Options cancelled (30,000 ) 15.00 Outstanding as of December 31, 2015 113,974 $ 10.58 8.50 Options vested December 31, 2015 104,891 (1) Includes 26,666 shares granted to Robert Farrell, the Company’s Chief Financial Officer, 13,333 of which are performance-based and vest upon continued service and achievement of a specific goal; and 13,333 of which are market-based and vest upon continued service and the Company’s achievement of certain stock price targets. All of these shares have an exercise price of $12.00. The amount of awards available to grant under the Plan is 38,977 as of December 31, 2015. 2014 Stock Plan In August 2014, the Company adopted the 2014 Stock Plan (the “2014 Plan”), which was approved by the Company’s stockholder at the Company’s Annual Meeting in September 2014. Under the 2014 Plan, the Company may grant up to 1,025,868 common shares in the form of incentive stock options, nonqualified stock options or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years. The following table is a summary of activity under the 2014 Plan: Common stock Weighted Average Weighted Average Remaining Contractual outstanding Exercise Price Term Balance December 31, 2013 - $ - - Options granted Employee 57,333 13.50 8.80 Outstanding as of December 31, 2014 57,333 13.50 8.80 Options granted Employee 166,467 12.50 8.20 Non-employee 15,000 12.30 8.20 Options cancelled (44,600 ) 12.00 Outstanding as of December 31, 2015 194,200 $ 8.91 9.50 Options vested December 31, 2015 83,922 The amount of awards available to grant under the 2014 Plan is 831,668 as of December 31, 2015. 2012 Preferred Stock Plan In July 2012, the Board of Directors adopted a new stock plan, the Management, Employee, Advisor and Director Preferred Stock Option Plan - 2012 Series B Convertible Preferred Stock Plan (“Preferred Stock Plan”). The purposes of the Preferred Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Management, Employees, Advisors and Directors and to promote the success of the Company’s business. Each share of Series B Preferred stock converts into 0.33 shares of common stock. The following table is a summary of activity under the Preferred Stock Plan: Preferred stock options Weighted Average Weighted Average Remaining Contractual outstanding Exercise Price Term Balance December 31, 2013 2,287,500 $ 0.47 8.50 Options granted Employee 200,000 2.21 8.80 Outstanding as of December 31, 2014 2,487,500 0.61 8.80 Options granted - - - Outstanding as of December 31, 2015 2,487,500 $ 0.61 7.80 Options vested December 31, 2015 2,483,333 The amount of awards available to grant under the Preferred Stock Plan is 512,500 as of December 31, 2015. Stock-based compensation expense for all plans for the years ended December 31, 2015 and 2014 is classified in the statements of operations as follows: For the Years Ended 2015 2014 Research and development $ 455 $ 412 General and administrative 1,015 890 Total $ 1,470 $ 1,302 At December 31, 2015, there was a total of approximately $2.0 million of unrecognized compensation cost, related to non-vested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.4 years. The fair value of the Company’s stock-based awards during the twelve months ended December 31, 2015 and 2014 were estimated using the following assumptions: Year Ended December 31, 2015 2014 Weighted-average volatility 262 % 288 % Weighted-average expected term 6.18 5.8 Expected dividends 0 % 0 % Risk-free investment rate 2 % 2 % Expected forfeiture rate 0 % 0 %

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Income Taxes	15. Income Taxes There is no provision for income taxes because we have incurred operating losses since inception and applied a full valuation allowance against all deferred tax assets. The reported amount of income tax expense attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below (amount in thousands): Year ended December 31, Loss before income taxes 2015 2014 United States $ (25,213 ) $ (27,277 ) Foreign - - Total Income (Loss) before income taxes $ (25,213 ) $ (27,277 ) Income tax expense (benefit) for the years ended December 31, 2015 and 2014 differed from the amounts computed by applying the statutory federal income tax rate of 34% to pretax income (loss) as a result of the following (amount in thousands): Year ended December 31, 2015 2014 Federal tax expense (benefit) at statutory rate $ (8,572 ) $ (9,274 ) State tax expense (benefit), net of federal tax effect (1,342 ) (1,334 ) R&D credit (326 ) (269 ) Non-deductible expenses 915 1,696 Change in valuation allowance 9,325 9,181 Total tax expense $ - $ - Year ended December 31, 2015 2014 Federal tax expense (benefit) at statutory rate (34.0 )% (34.0 )% State tax expense (benefit), net of federal tax effect (5.3 )% (4.9 )% R&D credit (1.3 )% (1.0 )% Non-deductible expenses 3.6 % 6.2 % Change in valuation allowance 37.0 % 33.7 % Total tax expense - % - % The significant components of deferred tax assets are as follows (amount in thousands): As of December 31, 2015 2014 Net operating loss carry-forward $ 23,241 $ 12,835 Tax credit carry-forward 857 504 Accrued liabilities 1,851 1,257 Capitalized start-up costs 15 15 Depreciation and amortization 3,206 2,833 Gross deferred tax assets 29,170 17,444 Intangibles (1,113 ) - Valuation allowance (29,170 ) (17,444 ) Net deferred tax liabilities $ (1,113 ) $ - F-24 The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company’s net deferred tax assets. The Company primarily considered such factors as the Company’s history of operating losses, the nature of the Company’s deferred tax assets and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying balance sheets. The valuation allowance increased by approximately $11.7 million and $9.2 million during the years ended December 31, 2015 and December 31, 2014, respectively. As of December 31, 2015, the Company had net federal and state net operating loss carry-forwards of approximately $58.3 million and $58.3 million, respectively. These net operating loss carry forwards will begin to expire, if not utilized, beginning in 2028 for both federal and state income tax purposes. The Company also has federal and state research and development credit carry-forwards of approximately $0.7 million and $0.2 million, respectively. The federal credits will expire if not utilized beginning in 2029. The California credits do not expire. The Tax Reform Act of 1986 and similar California legislation impose substantial restrictions on the use of net operating losses and tax credits in the event of an ownership change of a corporation. Accordingly, the Company’s ability to use net operating losses and credit carry forwards may be significantly limited in the future as a result of such an ownership change. The Company follows GAAP with regard recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded on the financial statements. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of tax expense, as necessary. A summary of unrecognized tax benefits is as follows (amount in thousands): Ending balance at December 31, 2014 $ 62 Increase (decrease) of unrecognized tax benefits taken in prior years - Increase (decrease) of unrecognized tax benefits related to current year 41 Increase (decrease) of unrecognized tax benefits related to settlements - Reductions to unrecognized tax benefits related lapsing statute of limitations - Ending balance at December 31, 2015 $ 103 The total amount of unrecognized tax benefits that if recognized, would affect the effective tax rate is $0. The Company has not incurred any interest or penalties as of December 31, 2015. The Company does not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions. The Company is mainly subject U.S. federal income taxes and California state taxes. There are no ongoing examinations by taxing authorities at this time. The Company’s tax years 2008 through 2015 will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any net operating loss credits.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2015
Related-Party Transactions [Abstract]
Related-Party Transactions	16. Related-Party Transactions Consulting Agreements The Company has an agreement with a NeuroAssets Sarl, a Swiss-based company to provide consulting services to the Company. Dr. David Lowe, who until October 2015, served as a Director of the Company is the president and chief executive officer of NeuroAssets. The Company recorded $0.6 million and $0.7 million in consulting fees to NeuroAssets for the years ended December 31, 2015 and 2014, respectively. The Company has an agreement with Joseph Rubinfeld to provide consulting services to the company. Joseph Rubinfeld was appointed to the Company’s Board of Directors in November 2012. The company recorded $100,000 and $142,000 in consulting fee for the years ended December 31, 2015 and 2014, respectively. Note Receivable On March 2, 2015, the Company loaned MedicoRx, Inc. $25,000 in an unsecured convertible promissory note. Joseph Rubinfeld is President and CEO and also a Board Member of Amarantus. The note provided the Company with first right of refusal on any additional investments, but there are no further obligations beyond the $25,000. The Company had a demand promissory note with Neurotrophics, which is due 365 days upon demand of the holder. At the option of the Company, the note and the accrued interest owed can be converted into common stock of the Company based on the closing price of the Company’s common stock on the day of the conversion. The conversion price if converted on December 31, 2015 would be $0.64 related to the note and accrued interest on the note and would convert to approximately 400,000 shares. Related party liabilities: As of December 31, 2015 2014 Promissory note, 2% interest $ 222 $ 222 Accrued interest 35 30 Total $ 257 $ 252

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events From January 1, 2016 to May 13, 2016, the Company issued the following preferred and common shares: ● In accordance with the original terms, converted 1,365 of Series E Preferred Stock into 17.1 million shares of common stock; ● In accordance with the original terms, converted 1,605 of Series H Preferred Stock into 28.8 million shares of common stock; ● In accordance with the original terms, issue Preferred Stock E dividends into 2.1 million shares of common stock; ● In accordance with the original terms, converted notes and interest $200,000 into 3.8 million shares of common stock; ● In accordance with the original terms, issue Preferred Stock H dividends into 2.3 million shares of common stock; ● Issued 0.5 million shares for services. See below for more detail regarding certain debt and equity related transactions. Sale of Series H Convertible Preferred Stock On January 27, 2016, the Company entered into a Securities Purchase Agreement (the “Series H SPA”) with an accredited investor for the sale of 1,166.666 (including 10% OID) shares of the Company’s 12% Series H Preferred Stock (the “Series H Preferred Stock”) and a warrant to purchase 495,833 shares of common stock (the “RD Warrant” and together with the Series H Preferred Stock, the “Securities”) in a registered direct offering (the “RD Offering”), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $1,000,000. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder. On February 19, 2016, the Company entered into a Securities Purchase Agreement (the “Series H SPA”) with an accredited investor for the sale of 3,300 (including 10% OID) shares of the Company’s 12% Series H Preferred Stock (the “Series H Preferred Stock”) and a warrant to purchase 13,200,000 shares of common stock (the “RD Warrant” and together with the Series H Preferred Stock, the “Securities”) in a registered direct offering (the “RD Offering”), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $3,000,000. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $0.40, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder. The warrants are immediately exercisable, expire on the five-year anniversary from issuance and are have an exercise price of $0.40 per share. An additional 525 shares of Series H were sold for $0.5 million in proceeds. Repurchase agreement of Series E Preferred Stock The Company also entered into repurchase agreements dated January 27, 2016 with two of its institutional investors pursuant to which the Company agreed to repurchase an aggregate 496 shares of Series H Preferred Stock and 496 shares of Series E Preferred Stock each at a price of $750,000 in 3 tranches in February 2016. Concurrently therewith, the Company has entered into an agreement with International Infusion LLC to provide funding of up to $1,500,000 to be used solely to repurchase such shares of Series H Preferred Stock. Sale of Series E Convertible Preferred Stock On February 8, 2016, the Company entered into a Securities Purchase Agreement (the “Series E SPA”) with institutional investors for the sale of 255.56 (including 10% OID) shares of the Company’s 12% Series E Preferred Stock (the “Series E Preferred Stock”) in a registered direct offering (the “RD Offering”), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $230,000. Each share of Series E Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price of $7.50 provided if the Holder delivers a conversion notice within 5 trading days following a period that the average of 3 consecutive VWAPs is less than $9.00, the conversion price shall be equal to lesser of the then conversion price and 65% of the lowest 2 consecutive VWAPs out of the prior 10 consecutive trading days prior to the delivery of the conversion notice. Investment - Convertible Note On March 1, 2016, the Company was issued a convertible note (the “Note”) from Theranostic Health, Inc. (“THI”) in exchange for $400,000. The Company provided the financing evidenced by the Note in order to facilitate the proposed acquisition by Avant Diagnostics, Inc. (“Avant”) of the assets and certain liabilities of THI. In a concurrent transaction, the Company has entered into a non-binding letter of intent to sell its wholly-owned subsidiary, Amarantus Diagnostics, Inc. to Avant for 80 million shares of common stock of Avant. The Note matures on February 28, 2017 and bears interest at 8% per annum payable at maturity in cash. The Note is convertible at any time at the option of the Company into shares of common stock of THI at a conversion price of $40.64 per share. The Note shall automatically convert into shares of common stock of THI upon a change of control of THI. It is expected that the Note will be assumed by Avant upon consummation of the transaction with THI. The conversion price of the Note is subject to weighted average anti-dilution price protection if the dilutive issuances are for less than $1 million and full ratchet anti-dilution protection if the dilutive issuances are for more than $1 million. The Note has events of default in for any default in the payment of principal or interest when due and for bankruptcy. Debt Financing On April 14, 2016, the Company entered into a Securities Purchase Agreement (the “Notes SPA”) with three institutional investors for the sale of an aggregate principal amount $1,500,000 (including 10% OID) 10% Senior Secured Convertible Promissory Notes due April 17, 2017 (the “Senior Secured Notes”) and a warrant to purchase 1,350,000 shares of common stock (the “Warrant”) in a private placement offering (the “Offering”). The gross proceeds to the Company from the Offering were $1,350,000. The Company used the net proceeds from the Offering to pay Lonza Walkerville for costs associated with development of its ESS product and working capital. Chardan Capital Markets acted as a placement agent in connection with the sale of the Senior Secured Notes and Warrants. Pursuant to the terms of the Notes SPA, the investors agreed to purchase additional aggregate principal amount of $1,555,556 (including 10% OID) of Senior Secured Notes and Warrants to purchase 1,400,000 shares of the Company’s common stock on the first trading date after the registration statement which is the subject of the registration rights agreement (discussed below) is filed, and an additional $1,388,889 (including 10% OID) of Senior Secured Notes and Warrants to purchase 1,250,000 shares of the Company’s common stock on the 61st day after such registration statement is declared effective or such earlier date as mutually agreed to among the investors, subject to the satisfaction of customary closing conditions. The principal amount of the Senior Secured Notes shall accrue interest at a rate equal to 12% per annum, payable on the Maturity Date in cash, or, at the Company’s option, in common stock or a combination thereof. At any time upon five (5) days written notice to the Investor, the Company may prepay any portion of the principal amount of the Senior Secured Notes and any accrued and unpaid interest at an amount equal to 120% of the then outstanding principal amount of the Senior Secured Notes and accrued interest or 130% if a Qualified Financing (as defined in the Senior Secured Notes) has occurred. At any time after the issuance date of the Senior Secured Notes until all amounts due have been paid in full, the Senior Secured Note shall be convertible, in whole or in part, into shares of common stock at the option of the holder, at any time and from time to time. The conversion price in effect on any conversion date shall be equal to the lowest of (i) $0.40, (ii) 75% of the lowest daily VWAP in the fifteen (15) trading days prior to the conversion date, or (iii) (A) if a Public Offering (as defined in the Senior Secured Note) that is not a Qualified Public Offering (as defined in the Senior Secured Note) has occurred, 75% or (B) if a Qualified Public Offering has occurred, 80% of the lowest of the (x) per share price of shares of common stock, and (y) the lowest conversion price, exercise price or exchange price of any common stock equivalents, that are sold or issued to the public in the Public Offering or the Qualified Public Offering, respectively. Effective on the closing (the “Mandatory Conversion Date”) of a Qualified Public Offering, the Qualified Public Offering Conversion Amount (as defined in the Senior Secured Note) shall automatically (without further act or deed of the Holder or the Company) convert (the “Mandatory Conversion”) into such number of shares of common stock as shall equal the quotient of (i) the Qualified Public Offering Conversion Amount outstanding as of and including the Mandatory Conversion Date, divided by (ii) a conversion price equal to the lowest of (i) the Conversion Price on the Mandatory Conversion Date, and (ii) eighty percent (80%) of the lowest of (x) the price per share at which the Company sells shares of common stock, and (y) the lowest conversion price, exercise price or exchange price of any common stock equivalents, if any, sold and or issued to the public in a Qualified Public Offering, if any. The Senior Secured Notes contain certain customary Events of Default (including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, including the transaction documents relating to the PP Offering, changes in control of the Company, filing of bankruptcy and the entering or filing of certain monetary judgments against the Company). Upon the occurrence of any such Event of Default the outstanding principal amount of the Senior Secured Notes, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become, at the Investor’s election, immediately due and payable in cash. Upon any Event of Default that results in acceleration of the Senior Secured Notes, the interest rate on the Senior Secured Notes shall accrue at an interest rate equal to the lesser of 24% per annum or the maximum rate permitted under applicable law. The Warrant issued in the Offering is exercisable on or prior to the close of business on the five-year anniversary of the issuance date at an exercise price of $0.40 per share. The Warrant may be exercised on a cashless basis in the event there is no effective registration statement covering the shares of common stock issuable upon exercise. In connection with the issuance of the Senior Secured Notes and Warrants, the Company entered into a Security Agreement and an Intellectual Property Security Agreement with the investor (the “Security Agreement”) pursuant to which the Company agreed to grant a security interest in all of its assets to the investor in order to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Senior Secured Notes. In addition, each of the Company’s wholly owned subsidiaries entered into a Subsidiary Guarantee, pursuant to which each of the subsidiaries, jointly and severally, agreed to guarantee the obligations of the Company under the Senior Secured Notes. In addition, the Company and certain of its investors agreed to a lock-up and leak-out agreements pursuant to which the investors agreed to certain trading restrictions with respect to its holdings of preferred stock and convertible notes of the Company. The lock-up agreements remain in force until $67.5 million of aggregate trading volume, calculated from the date that a registration statement underlying the shares of the Senior Secured Notes has been declared effective by the Securities and Exchange Commission. The leak-out restrictions, restrict certain investors to ranges of trading to no more than 2.5% to 15% of the average daily volume of the Company’s common stock. The leak out agreements remain in force until $67.5 million of aggregate trading volume, calculated from the date that a registration statement underlying the shares of the Senior Secured Notes has been declared effective by the Securities and Exchange Commission. In partial consideration of the investors’ agreeing to the trading restrictions, the Company agreed to amendments of the terms of the Series E and Series H Preferred in order to provide additional voting rights for those investors at its upcoming annual meeting of shareholders. The Company entered into a Registration Rights Agreement with the investors in which it agreed to register the shares of common stock issuable upon conversion or as interest under the Senior Secured Notes and the shares of common stock issuable upon exercise of the Warrants which registration shall be filed within 10 days. The Company agreed to use its best efforts to have the Registration Statement declared effective within 45 days of filing. The Company is required to pay partial liquidated damages in cash of 2% of the subscription amount paid by each holder if: (i) the Company fails to file a request for acceleration of the registration Statement within five trading days of the date that the Company is notified that such Registration Statement will not be “reviewed” or will not be subject to further review, or (ii) the Company fails to file a pre-effective amendment and otherwise respond in writing to comments within ten (10) calendar days after the receipt of comments, or (iii) the registration statement is not declared effective within 45 days of filing, or (iv) after the effective date of, such Registration Statement ceases for any reason to remain continuously effective. If the Company fails to pay any partial liquidated damages in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum. In connection with the Offering, the Company also agreed that at its annual meeting of shareholders to be held on or before June 6, 2016, to seek the approval of its shareholders to increase its authorized common stock and effect a reverse stock split. Notes payable exchange for Senior Secured Convertible Promissory Notes On March 9, 2016 two investors assigned their 12% Promissory notes to a third investor in return for payment of principal and interest, $112,000 and $224,000 respectively. The third investor, on the same day, entered into two separate Exchange Agreements with the Company. The Exchange Agreements allow the third investor to exchange the 12% Promissory Notes for two separate 12% Senior Secured Convertible Promissory Notes, $100,000 and $200,000 respectively. During March 2016 the $100,000 note was converted to 1,989,669 Common shares. The $200,000 12% Senior Secured Convertible Promissory Note is still outstanding. Acquisition of Amarantus Diagnostics by Avant Diagnostics, Inc. On May 11, 2016 (the “ Effective Date Exchange Agreement AMDX Acquisition Avant paid to Amarantus aggregate consideration of 80,000,000 shares of Avant’s common stock for the AMDX Acquisition, subject to the issuance of additional shares upon the occurrence of certain events set forth in the Exchange Agreement (the “ AMDX Consideration AMDX owned the rights to MSPrecise®, a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation, has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns intellectual property for the diagnosis of Parkinson's disease (NuroPro). In connection with the Exchange Agreement, on the Effective Date, the Avant issued to Amarantus a convertible promissory note in the principal amount of $50,000 (the " Note Amarantus Diagnostics Sale On May 11, 2016 (the “ Effective Date Exchange Agreement AMDX Buyer AMDX Sale Board The Buyer paid aggregate consideration of 80,000,000 shares of its common stock to Amarantus for the AMDX Sale, subject to the issuance of additional shares upon the occurrence of certain events set forth in the Exchange Agreement (the “ AMDX Consideration Measurement Period ® Additional AMDX Consideration Lock-Up Period At the end of the Lock-Up Period, in the event that the AMDX Consideration has a value equal to or less than $3,000,000 in the aggregate on the date the Lock-Up Period expires (based on the average closing “print’ prices at 4:00 p.m. of the Buyer’s common stock on the last five days prior to the date the Lock-Up Period expires as listed or quoted on any national securities exchange or over-the-counter market (including any tier maintained by the OTC Markets, Inc.), as the case may be (the “ Lock-Up Termination Date Closing Price Lock-Up Termination Date Additional Common Stock The Exchange Agreement includes customary representations, warranties and covenants of the Company, AMDX and the Buyer made solely for the benefit of the parties to the Exchange Agreement. The assertions embodied in those representations and warranties were made solely for purposes of the contract among Amarantus, AMDX and the Buyer and may be subject to important qualifications and limitations agreed to by the Amarantus, AMDX and the Buyer in connection with the negotiated terms. Moreover, some of those representations and warranties may not be accurate or complete as of any specified date, may be subject to a contractual standard of materiality different from those generally applicable to stockholders or may have been used for purposes of allocating risk among Amarantus, AMDX and the Buyer rather than establishing matters as facts. Investors are not third-party beneficiaries under the Exchange Agreement and should not rely on the representations, warranties and covenants in the Exchange Agreement or any description thereof as characterizations of the actual state of facts of the Company, AMDX and the Buyer or any of their respective subsidiaries or affiliates. In connection with the Exchange Agreement, on the Effective Date, the Company entered into an escrow agreement dated May 11, 2016 by and among Amarantus, the Buyer, AMDX, holders of the Company’s secured debt (“ Secured Holders Escrow Agreement Escrow Shares In connection with the Exchange Agreement, on the Effective Date, the Buyer issued a convertible promissory note to Amarantus pursuant to which the Company purchased a note with aggregate principal amount of $50,000 for an aggregate purchase price of $50,000 (the " Note Issuance of Senior Secured Convertible Promissory Notes and Warrants On May 13, 2016, two institutional investors purchased $1,540,000 (including 10% OID) principal amount of 10% Senior Secured Convertible Promissory Notes due May 13, 2017 (the “Senior Secured Notes”) pursuant to a previously disclosed Securities Purchase Agreement (the “Notes SPA”) entered into on April 14, 2016. In connection with the sale of the Senior Secured Notes, Amarantus issued warrants to purchase an aggregate 1,400,000 shares of common stock to the institutional investors. The warrant issued pursuant to the Notes SPA are exercisable on or prior to the close of business on the five-year anniversary of the issuance date at an exercise price of $0.40 per share. The warrants may be exercised on a cashless basis in the event there is no effective registration statement covering the shares of common stock issuable upon exercise. The warrants described above were not registered under the Securities Act of 1933, as amended (the " Securities Act

Significant Accounting Polici25

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Reclassification	Reclassification
Use of Estimates	Use of Estimates
Certain Significant Risks and Uncertainties	Certain Significant Risks and Uncertainties
Concentration of Credit Risk	Concentration of Credit Risk
Cash and Cash Equivalents	Cash and Cash Equivalents
Property and Equipment	Property and Equipment Equipment 3 years Computer equipment 2 years Furniture and fixtures 3 years
Accounting for Business Combinations	Accounting for Business Combinations - Contingent consideration assumed in a business combination is remeasured at fair value each reporting period and any change in the fair value from either the passage of time or events occurring after the acquisition date, is recorded in results from operations. The results of operations are included from the acquisition date in the financial statements for all businesses acquired.
Goodwill and Other Identifiable Intangibles	Goodwill and Other Identifiable Intangibles - The Company estimates the fair value of the reporting unit using a market approach in combination with a discounted operating cash flow approach. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. An adjustment to goodwill will be recorded for any goodwill that is determined to be impaired. The Company tests goodwill for impairment at least annually in conjunction with the preparation of its annual business plan, or more frequently if events or circumstances indicate it might be impaired. For reporting units with zero or negative carrying amounts, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not that a goodwill impairment exists. In determining whether it is more likely than not that goodwill impairment exists, an entity should consider whether there are any adverse qualitative factors indicating that impairment may exist. As of December 31, 2015, the Company performed a quantitative goodwill impairment test and determined that goodwill was not impaired.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
Research and Development Expenditures	Research and Development Expenditures
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined under the standard as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The standard also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value: ● Level 1 ● Level 2 ● Level 3
Stock-Based Compensation	Stock-Based Compensation Grant-date fair value is determined using the Black-Scholes option pricing model, which requires the use of the following assumptions: Expected Term Expected Volatility Risk-Free Interest Rate Expected Dividend Forfeiture Rate The fair value of stock options granted to nonemployees is recognized over the period in which the related services are received.
Debt Extinguishment	Debt Extinguishment -
Share-settled Debt	Share-settled Debt – Sequencing As of October 2015, the Company adopted a sequencing policy whereby all future instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.
Preferred Stock	Preferred Stock
Convertible Financial Instruments	Convertible Financial Instruments When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Deemed dividends are also recorded for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Common Stock Purchase Warrants and Derivative Financial Instruments	Common Stock Purchase Warrants and Derivative Financial Instruments - Common stock purchase warrants and other derivative financial instruments are classified as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). Contracts which (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions that do not qualify for the scope exception are classified as equity or liabilities. The Company assesses classification of its common stock purchase warrants and other derivatives at each reporting date to determine whether a change in classification between equity and liabilities is required.
Debt Discounts	Debt Discounts -
Income Taxes	Income Taxes In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made. Interest and penalties related to uncertain tax positions are recorded in the provision for income tax expense on the consolidated statements of operations.
Net Loss Per Common Shareholder	Net Loss Per Common Shareholder -
Segments	Segments
Subsequent Events	Subsequent Events
Adoption of Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements In August 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-15, “Interest - Imputation of Interest: Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements”, which clarifies the treatment of debt issuance costs from line-of-credit arrangements after the adoption of ASU No. 2015-03, “Interest - Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs”. In particular, ASU No. 2015-15 clarifies that the SEC staff would not object to an entity deferring and presenting debt issuance costs related to a line-of-credit arrangement as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of such arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement. The Company adopted ASU No. 2015-15 and its adoption did not have a material impact on the consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “ Revenue from Contracts with Customers In August 2014, the FASB issued ASU No. 2014-15, “ Presentation of Financial Statements — Going Concern (Subtopic 205-40) — Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” In November 2014, the FASB issued ASU No. 2014-16, Derivatives and Hedging ("ASU 2014-16"), which clarifies how current GAAP should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. The amendments in this Update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption, including adoption in an interim period, is permitted. The Update does not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The Company will adopt ASU 2014-16 on January 1, 2016 and does not believe the adoption of this ASU to have a material impact on the combined and consolidated financial statements. ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities ASU No. 2016-02, Leases (Topic 842) Leases (Topic 840)

Significant Accounting Polici26

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Significant Accounting Policies [Abstract]
Schedule of estimated useful lives of property plant and equipment	Equipment 3 years Computer equipment 2 years Furniture and fixtures 3 years

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Summary of supplemental pro forma information	For the year end December 31, 2014 (Unaudited) Net Sales $ - Operating Expenses 23,335 Loss from operations (23,335 ) Total other expenses (6,378 ) Net Loss (29,713 ) Basic and diluted net loss per common share $ (0.04 )
Schedule of purchase price to Company's balance sheet	January 8, 2015 Intangibles - Acquisition Diogenix (IPR&D) $ 2,861 Prepaid expenses and other current assets 13 Property and equipment, net 40 Goodwill 7,967 Total assets 10,881 Earn-out liability (917 ) Deferred tax liability (1,113 ) Net assets acquired $ 8,851

Research and Development Lice28

Research and Development Licenses and Patent Acquired (Tables)	12 Months Ended
	Dec. 31, 2015
Research and Development Licenses and Patent Acquired [Abstract]
Summarizes of intangible assets	As of December 31, 2015 2014 Intangibles - Acquisition Diogenix (IPR&D) $ 2,861 $ - Licenses - 1,497 Total intangible assets $ 2,861 $ 1,497

Senior Secured Convertible Pr29

Senior Secured Convertible Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Summary of outstanding senior secured convertible notes	Stated Remaining Issue Date Maturity Date Interest Rate Conversion Terms Face Value Debt Discount Carrying Value Delafield Investments Ltd 9/30/2015 9/29/2016 12 % $ 0.43 $ 3,056 $ (2,286 ) $ 770 Dominion Capital LLC 9/30/2015 9/29/2016 12 % $ 0.43 2,096 (1,568 ) 528 US 1000 LLC 12/07/2015 12/6/2016 12 % N/A 100 - 100 Ending balance as of December 31, 2015 $ 5,252 $ (3,854 ) $ 1,398

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Measurements [Abstract]
Schedule of financial assets and liabilities that are measured at fair value on a recurring basis	Fair value measured at December 31, 2015 Fair value at Quoted Significant other observable Significant unobservable December 31, markets inputs inputs 2015 (Level 1) (Level 2) (Level 3) Derivative liability $ - $ - $ 2,073 $ 2,073 Warrant liability - - 3,025 3,025 Share-settled debt - - 521 521 Total fair value $ - $ - $ 5,619 $ 5,619
Summary of changes in Level 3 liabilities measured at fair value	Warrant Liability Earn-out Embedded Conversion Feature Share-settled Debt Total January 1, 2014 $ - $ 5,859 $ - $ 5,859 Conversion of 8% senior convertible debentures to common stock - (5,542 ) - (5,542 ) Change in fair value - (317 ) - (317 ) December 31, 2014 - - - - Issuance of convertible notes - 3,936 - 3,936 Issuance of share-settled debt - - 275 275 Addition of earn-out liability 917 917 Issuance of warrants 5,631 - - 5,631 Conversion of 8% senior convertible debentures to common stock - (363 ) - (363 ) Change in fair value (2,606 ) (917 ) (1,500 ) 246 (4,777 ) December 31, 2015 $ 3,025 - $ 2,073 $ 521 $ 5,619
Schedule of fair value of the warrants determined using the Monte Carlo simulation	As of December 31, 2015 Warrant Liability Derivative Liability Share-settled Debt Contractual life (years) 4.8 0.8 0.4 Annualized volatility* 71 % 70 % 70 % Conversion price $ 2.00 $ 2.50 $ 0.30 Expected dividends 0 % 0 % 0 % Risk-free investment rate 1.7 % 0.6 % 0.6 % * The Company uses comparable companies within the same industry to derive at the 70% annualized volatility.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Net Loss Per Share [Abstract]
Schedule of computation of the basic and diluted net loss per share	As of December 31, 2015 2014 Numerator: Net loss $ (25,214 ) $ (27,277 ) Preferred stock dividend (3,595 ) (875 ) Deemed dividends on convertible preferred stock (8,249 ) - Net loss attributable to common stockholders $ (37,058 ) $ (28,152 ) Denominator: Weighted Average Common stock outstanding 8,878,000 4,926,000 Basic and diluted net loss per share $ (4.17 ) $ (5.71 ) Potentially dilutive securities consist of: As of December 31, 2015 2014 Outstanding common stock options 308,000 201,000 Outstanding preferred stock option 829,000 829,000 Common Stock Purchase Warrants 12,810,000 311,000 Related party liability 401,000 20,000 Convertible senior secured promissory notes and accrued interest 12,382,000 - Convertible preferred stock Series C 5,000 5,000 Convertible preferred stock Series D - 289,000 Convertible preferred stock Series E 1,302,000 375,000 Convertible preferred stock Series H 6,534,000 - Potentially dilutive securities 35,021,000 2,030,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Schedule of sponsored research arrangements future payments	2016 $ 150 Total $ 150
Schedule of future minimum rental payments for operating leases	2016 $ 139 Total $ 139

Temporary Equity (Table)

Temporary Equity (Table)	12 Months Ended
	Dec. 31, 2015
Temporary Equity [Abstract]
Schedule of temporary equity	Series H convertible Shares Value Total temporary equity as of December 31, 2014 - $ - Proceeds from sale of Series H preferred stock, net of issuance costs of $0.4 million 4,588 3,796 Beneficial conversion feature of Series H convertible preferred stock - (1,260 ) Deemed dividends related to immediate accretion of beneficial conversion feature of Series H convertible preferred stock - 1,260 Fair Value of common stock warrant issued with Series H convertible preferred stock - (2,534 ) Common stock issued in conversion of Series H convertible preferred stock (1,772 ) (1,772 ) Deemed dividend on conversion of Series H convertible preferred stock to common stock - 1,301 Deemed dividend related to accretion of redemption value - 2,363 Total temporary equity as of December 31, 2015 2,816 $ 3,154

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity [Abstract]
Schedule of warrant activities	Weighted Average Number of Weighted Average Remaining Contractual Warrants Exercise Price Term Outstanding as of December 31, 2013 563,689 $ 9.00 1.69 Issued in connection with warrant exchange 300,000 18.00 Exercised (552,777 ) 9.00 Outstanding as of December 31, 2014 310,912 18.00 3.06 Issued in connection with various financings (1) 5,046,705 2.00 Reset Warrants (2) 7,460,353 0.71 Expired and cancellation (8,020 ) 9.00 Outstanding as of December 31, 2015 12,809,950 $ 1.14 4.77 (1) Approximately 4,547,000 warrants contain “down round protection” and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period. (2) Certain warrants contain aggregate exercise provisions, and upon a reset the exercise price is decreased and the amount of common stock available under the warrant agreement increases. During the 4th quarter a reset occurred decreasing the exercise price from $2.00 to $0.71 and increasing the amount of common stock available to be issued from 4,106,000 to 11,566,000

Stock Option Plans (Tables)

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock-based compensation expense classified in statements of operations	For the Years Ended 2015 2014 Research and development $ 455 $ 412 General and administrative 1,015 890 Total $ 1,470 $ 1,302
Schedule of share-based payment award, stock options, valuation assumptions	Year Ended December 31, 2015 2014 Weighted-average volatility 262 % 288 % Weighted-average expected term 6.18 5.8 Expected dividends 0 % 0 % Risk-free investment rate 2 % 2 % Expected forfeiture rate 0 % 0 %
2008 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of share-based compensation, stock options activity	Common stock Weighted Weighted Average Remaining options Average Contractual outstanding Exercise Price Term Balance December 31, 2013 46,275 $ 7.50 8.00 Options granted (weighted-average fair value of $0.08) Employee (1) 83,333 13.50 8.20 Non-employee 22,009 12.00 8.20 Options cancelled (7,643 ) 10.50 Outstanding as of December 31, 2014 143,974 11.50 7.80 Options cancelled (30,000 ) 15.00 Outstanding as of December 31, 2015 113,974 $ 10.58 8.50 Options vested December 31, 2015 104,891 (1) Includes 26,666 shares granted to Robert Farrell, the Company’s Chief Financial Officer, 13,333 of which are performance-based and vest upon continued service and achievement of a specific goal; and 13,333 of which are market-based and vest upon continued service and the Company’s achievement of certain stock price targets. All of these shares have an exercise price of $12.00.
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of share-based compensation, stock options activity	Common stock Weighted Average Weighted Average Remaining Contractual outstanding Exercise Price Term Balance December 31, 2013 - $ - - Options granted Employee 57,333 13.50 8.80 Outstanding as of December 31, 2014 57,333 13.50 8.80 Options granted Employee 166,467 12.50 8.20 Non-employee 15,000 12.30 8.20 Options cancelled (44,600 ) 12.00 Outstanding as of December 31, 2015 194,200 $ 8.91 9.50 Options vested December 31, 2015 83,922
2012 Preferred Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of share-based compensation, stock options activity	Preferred stock options Weighted Average Weighted Average Remaining Contractual outstanding Exercise Price Term Balance December 31, 2013 2,287,500 $ 0.47 8.50 Options granted Employee 200,000 2.21 8.80 Outstanding as of December 31, 2014 2,487,500 0.61 8.80 Options granted - - - Outstanding as of December 31, 2015 2,487,500 $ 0.61 7.80 Options vested December 31, 2015 2,483,333

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Schedule of loss before income taxes from operations	Year ended December 31, Loss before income taxes 2015 2014 United States $ (25,213 ) $ (27,277 ) Foreign - - Total Income (Loss) before income taxes $ (25,213 ) $ (27,277 )
Schedule of components of income tax expense (benefit)	Year ended December 31, 2015 2014 Federal tax expense (benefit) at statutory rate $ (8,572 ) $ (9,274 ) State tax expense (benefit), net of federal tax effect (1,342 ) (1,334 ) R&D credit (326 ) (269 ) Non-deductible expenses 915 1,696 Change in valuation allowance 9,345 9,181 Total tax expense $ - $ - Year ended December 31, 2015 2014 Federal tax expense (benefit) at statutory rate (34.0 )% (34.0 )% State tax expense (benefit), net of federal tax effect (5.3 )% (4.9 )% R&D credit (1.3 )% (1.0 )% Non-deductible expenses 3.6 % 6.2 % Change in valuation allowance 37 % 33.7 % Total tax expense - % - %
Schedule of components of deferred tax assets	As of December 31, 2015 2014 Net operating loss carry-forward $ 23,241 $ 12,835 Tax credit carry-forward 857 504 Accrued liabilities 1,851 1,257 Capitalized start-up costs 15 15 Depreciation and amortization 3,206 2,833 Gross deferred tax assets 29,170 17,444 Intangibles (1,113 ) - Valuation allowance (29,170 ) (17,444 ) Net deferred tax liabilities $ (1,113 ) $ -
Schedule of unrecognized tax benefits	Ending balance at December 31, 2014 $ 62 Increase (decrease) of unrecognized tax benefits taken in prior years - Increase (decrease) of unrecognized tax benefits related to current year 41 Increase (decrease) of unrecognized tax benefits related to settlements - Reductions to unrecognized tax benefits related lapsing statute of limitations - Ending balance at December 31, 2015 $ 103

Related-Party Transactions (Tab

Related-Party Transactions (Table)	12 Months Ended
	Dec. 31, 2015
Related-Party Transactions [Abstract]
Schedule of accrued liability	Related party liabilities: As of December 31, 2015 2014 Promissory note, 2% interest $ 222 $ 222 Accrued interest 35 30 Total $ 257 $ 252

General (Details)

General (Details)	12 Months Ended
	Dec. 31, 2015
General (Textual)
Reverse stock split, Description	The reverse stock split became effective on June 10, 2015. Upon the effectiveness of the reverse stock split, (i) every one hundred and fifty shares of outstanding common stock was combined into one share of common stock, (ii) the number of shares of common stock into which each outstanding warrant or option to purchase common stock is exercisable was proportionally decreased, (iii) the exercise price of each outstanding warrant or option to purchase common stock was proportionately increased, and (iv) the conversion ratio for each share of preferred stock outstanding was proportionately reduced.
Reverse stock split, retroactive basis	Unless otherwise indicated, all of the share numbers, share prices and exercise prices in these consolidated financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-150 reverse stock split.

Significant Accounting Polici39

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2015
Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Useful life	3 years
Computer equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Useful life	2 years
Furniture and fixtures [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Useful life	3 years

Significant Accounting Polici40

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Significant Accounting Policies [Abstract]
Impairment charges of intangible assets
Research and development costs	$ 13,256	$ 13,762

Business Combinations (Details)

Business Combinations (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)$ / shares
Business Combinations [Abstract]
Net Sales
Operating Expenses	$ 23,335
Loss from operations	(23,335)
Total other expenses	(6,378)
Net Loss	$ (29,713)
Basic and diluted net loss per common share | $ / shares	$ (0.04)

Business Combinations (Details

Business Combinations (Details 1) - USD ($) $ in Thousands	Dec. 31, 2015	Jan. 08, 2015
Business Combinations [Line Items]
Goodwill	$ 7,967
DioGenix, Inc [Member]
Business Combinations [Line Items]
Intangibles - Acquisition Diogenix (IPR&D)		$ 2,861
Prepaid expenses and other current assets		13
Property and equipment, net		40
Goodwill		7,967
Total assets		10,881
Earn-out liability		(917)
Deferred tax liability		(1,113)
Net assets acquired		$ 8,851

Business Combinations (Detail43

Business Combinations (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jan. 08, 2015	Dec. 31, 2015	Mar. 31, 2014
Business Combinations (Textual)
Stock price per share			$ 6
Cash consideration		$ 8,900
DioGenix, Inc [Member]
Business Combinations (Textual)
Consideration paid in shares	662,526
Stock price per share	$ 12
Cash consideration	$ 900
Total consideration	8,851
Contingent payment in cash	$ 2,000
Discount rate	30.40%

Research and Development Lice44

Research and Development Licenses and Patent Acquired (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 2,861	$ 1,497
Acquisition Diogenix (IPR&D) [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets	$ 2,861
Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Total intangible assets		$ 1,497

Research and Development Lice45

Research and Development Licenses and Patent Acquired (Details Textual) - USD ($)	Jan. 08, 2015	Jan. 31, 2014	Dec. 31, 2015
Intangible assets (Textual)
Payment to acquire intangible asset		$ 750,000
Asset Acquired Research and Development [Member]
Intangible assets (Textual)
Previously disclosed option to acquire intellectual property rights	$ 4,000,000
Business combination consideration transsferred	$ 5,000,000
Payment to acquire intangible asset			$ 4,000,000

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jul. 09, 2015	Dec. 31, 2015
Notes payable (Textual)
Debt instrument, face amount		$ 105,000
Interest rate		2.00%
Notes Payable Securities Purchas Agreement [Member]
Notes payable (Textual)
Debt instrument, face amount	$ 1,000,000
Interest rate	12.00%
Maturity Date	Jul. 9, 2016
Percentage senior secured convertible notes	12.00%
Beneficial conversion feature	$ 600,000
Notes Payable	$ 600,000

Senior Secured Convertible Pr47

Senior Secured Convertible Promissory Notes (Details)	12 Months Ended
	Dec. 31, 2015USD ($)$ / shares
Debt Instrument [Line Items]
Stated Interest Rate	2.00%
Face Value	$ 105,000
Accumulated Debt Discount	(3,854,000)
Carrying Value	$ 1,398,000
Delafeild Investments Ltd [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date	Sep. 30, 2015
Maturity Date	Sep. 29, 2016
Stated Interest Rate	12.00%
Conversion Terms | $ / shares	$ 0.43
Face Value	$ 3,056,000
Accumulated Debt Discount	(2,286,000)
Carrying Value	$ 770,000
Dominion Capital LLC [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date	Sep. 30, 2015
Maturity Date	Sep. 29, 2016
Stated Interest Rate	12.00%
Conversion Terms | $ / shares	$ 0.43
Face Value	$ 2,096,000
Accumulated Debt Discount	(1,568,000)
Carrying Value	$ 528,000
US 1000 LLC [Member] | Senior Secured Convertible Promissory Notes [Member]
Debt Instrument [Line Items]
Issue Date	Jul. 12, 2015
Maturity Date	Jun. 12, 2016
Stated Interest Rate	12.00%
Conversion Terms | $ / shares
Face Value	$ 100,000
Accumulated Debt Discount
Carrying Value	$ 100,000

Senior Secured Convertible Pr48

Senior Secured Convertible Promissory Notes (Details Textual) - USD ($)	Jul. 09, 2015	Jul. 01, 2015	Sep. 30, 2015	Aug. 27, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 07, 2015
Senior Secured Convertible Promissory Notes (Textual)
Interest rate					2.00%
Debt instrument, face amount					$ 105,000
Exercise price					$ 0.40
Amortization of debt discount					$ 1,298,000	$ 582,000
Conversion of stock amount					$ 1,659,000
Notes Payable Securities Purchas Agreement [Member]
Senior Secured Convertible Promissory Notes (Textual)
Interest rate	12.00%
Debt instrument, face amount	$ 1,000,000
Maturity Date	Jul. 9, 2016
Beneficial conversion feature	$ 600,000
12% Senior Secured Convertible Promissory Note and Warrants [Member]
Senior Secured Convertible Promissory Notes (Textual)
Description of debt instrument					The principal amount of the Senior Secured Notes shall accrue interest at a rate equal to 12% per annum, payable on the Maturity Date in cash, or, at the Company's option, in common stock or a combination thereof. At any time upon five (5) days written notice to the Investor, the Company may prepay any portion of the principal amount of the Senior Secured Notes and any accrued and unpaid interest at an amount equal to 120% of the then outstanding principal amount of the Senior Secured Notes and accrued interest or 130% if a Qualified Financing (as defined in the Senior Secured Notes) has occurred.
12% Senior Secured Convertible Promissory Note and Warrants [Member] | Secured Debt [Member]
Senior Secured Convertible Promissory Notes (Textual)
Description of debt instrument					The conversion price in effect on any conversion date shall be equal to the lowest of (i) $2.50, (ii) 75% of the lowest daily VWAP in the fifteen (15) trading days prior to the conversion date, or (iii) (A) if a Public Offering (as defined in the Senior Secured Note) that is not a Qualified Public Offering (as defined in the Senior Secured Note) has occurred, 75% or (B) if a Qualified Public Offering has occurred, 80% of the lowest of the (x) per share price of shares of common stock, and (y) the lowest conversion price, exercise price or exchange price of any common stock equivalents, that are sold or issued to the public in the Public Offering or the Qualified Public Offering, respectively.
Beneficial conversion feature					$ 1,045
12% Senior Secured Convertible Promissory Note and Warrants [Member] | Exchange Agreement [Member]
Senior Secured Convertible Promissory Notes (Textual)
Debt instrument, face amount			$ 3,000,000
Warrant to purchase			1,299,000
Exercise price			$ 2
Description of debt instrument					The debt discount associated with Dominion Notes was $1.6 million, and expected to be amortized in 9 months.
Convertible promissory notes			$ 3,000,000
Debt conversion converted instruments shares					3,415,574
Debt conversion converted instrument amount					$ 900,000
Amortization of debt discount					900,000
Extinguishment of debt					1,300,000
Derivative liability					400,000
Conversion of stock amount					$ 1,700,000
12% Senior Secured Convertible Promissory Note and Warrants [Member] | Notes Payable Securities Purchas Agreement [Member]
Senior Secured Convertible Promissory Notes (Textual)
Interest rate		12.00%	12.00%
Debt instrument, face amount			$ 3,100,000	$ 75,000
Maturity Date		Apr. 2, 2016	Sep. 29, 2016	Feb. 24, 2016
Warrant to purchase			1,299,000
Gross proceeds			$ 2,700,000
Description of debt instrument			The warrants are exercisable after March 31, 2016 and terminate on the five-year anniversary of that date. The warrants had an initial exercise price of $2.00 per share. The warrants have an aggregate exercise provision that upon reset the amount of warrant coverage increases proportionally to the decrease in exercise price.		Debt discount associated with Delafield Notes was $2.3 million, and expected to be amortized in 9 months.
Percentage of OID		10.00%	10.00%
Convertible promissory notes		$ 600,000					$ 100,000
Debt conversion converted instruments shares		766
Amortization of debt discount					$ 2,300,000

Share-settled Debt (Details)

Share-settled Debt (Details)	Oct. 14, 2015USD ($)Tradingdays	Jul. 09, 2015USD ($)	Jul. 01, 2015	Nov. 20, 2015USD ($)	Sep. 30, 2015USD ($)	Aug. 27, 2015USD ($)Tradingdays	Dec. 31, 2015USD ($)
Share-Settled Debt (Textual)
Principal amount							$ 105,000
Change in fair value of the Notes							$ 200,000
Notes Payable Securities Purchas Agreement [Member]
Share-Settled Debt (Textual)
Principal amount		$ 1,000,000
Maturity Date		Jul. 9, 2016
20% Convertible Promissory Notes [Member] | Notes Payable Securities Purchas Agreement [Member]
Share-Settled Debt (Textual)
Principal amount					$ 3,100,000	$ 75,000
Debt conversion, description						The conversion price is 55% of the lowest VWAP of the prior 5 trading days.
Maturity Date			Apr. 2, 2016		Sep. 29, 2016	Feb. 24, 2016
Trading days | Tradingdays						5
15% Promissory Notes [Member] | Notes Payable Securities Purchas Agreement [Member]
Share-Settled Debt (Textual)
Principal amount	$ 150,000
Debt conversion, description	The conversion price is 55% of the lowest VWAP of the prior 5 trading days.
Maturity Date	Nov. 4, 2016
Trading days | Tradingdays	5
Convertible Promissory Note [Member]
Share-Settled Debt (Textual)
Principal amount				$ 50,000
Debt conversion, description				The conversion price is 50% of the average of the lowest 3 closing prices for 10 trading days prior to but not including the conversion date.

Fair Value Measurements (Detail

Fair Value Measurements (Details) $ in Thousands	Dec. 31, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share settled debt	$ 521
Fair Value Measurements Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Warrant liability
Share settled debt
Total fair value
Fair Value Measurements Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 2,073
Warrant liability	3,025
Share settled debt	521
Total fair value	5,619
Fair Value Measurements Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share settled debt	$ 521

Fair Value Measurements (Deta51

Fair Value Measurements (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary of changes in the fair value of the Level 3 financial liabilities
Begining balance		$ 5,859
Issuance of convertible notes	$ 3,936
Issuance of warrants	5,631	(3,867)
Conversion of 8% senior convertible debentures to common stock	(363)	(5,542)
Issuance of share-settled debt	275
Change in fair value	(4,777)	$ (317)
Ending balance	$ 5,619
Fair Value, Inputs, Level 3 [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
Begining balance
Ending balance	$ 8,365
Fair Value, Inputs, Level 3 [Member] | Share-settled Debt [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
Begining balance
Issuance of convertible notes
Conversion of 8% senior convertible debentures to common stock
Issuance of share-settled debt	$ 275
Change in fair value	246
Ending balance	$ 521
Fair Value, Inputs, Level 3 [Member] | Embedded Conversion Feature [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
Begining balance		$ 5,859
Issuance of convertible notes	$ 3,936
Conversion of 8% senior convertible debentures to common stock	(363)	(5,542)
Change in fair value	(1,500)	$ (317)
Ending balance	2,073
Fair Value, Inputs, Level 3 [Member] | Earn out- Liability [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
Addition of earn-out liability	917
Change in fair value	$ (917)
Ending balance
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Summary of changes in the fair value of the Level 3 financial liabilities
Begining balance
Issuance of convertible notes
Issuance of warrants	$ 5,631
Conversion of 8% senior convertible debentures to common stock
Change in fair value	(2,606)
Ending balance	$ 3,025

Fair Value Measurements (Deta52

Fair Value Measurements (Details 2)	12 Months Ended
	Dec. 31, 2015$ / shares
Summary of fair value of the warrants
Annualized volatility	70.00%
Share-settled Debt [Member]
Summary of fair value of the warrants
Contractual life (years)	4 months 24 days
Annualized volatility	70.00%	[1]
Conversion price	$ 0.30
Expected dividends	0.00%
Risk-free investment rate	0.60%
Warrant Liability [Member]
Summary of fair value of the warrants
Contractual life (years)	4 years 9 months 18 days
Annualized volatility	71.00%	[1]
Conversion price	$ 2
Expected dividends	0.00%
Risk-free investment rate	1.70%
Derivative Liability [Member]
Summary of fair value of the warrants
Contractual life (years)	9 months 18 days
Annualized volatility	70.00%	[1]
Conversion price	$ 2.50
Expected dividends	0.00%
Risk-free investment rate	0.60%
[1]	The Company uses comparable companies within the same industry to derive at the 70% annualized volatility.

Fair Value Measurements (Deta53

Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Measurements [Abstract]
Earn-out liability	$ 0
Debt conversion, converted instrument, Rate		8.00%
Annualized volatility	70.00%

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net loss	$ (25,214)	$ (27,277)
Preferred stock dividend	3,595	$ 875
Deemed dividends on convertible preferred stock	(8,249)
Net loss attributable to common stockholders	$ (37,058)	$ (28,152)
Denominator:
Weighted Average Common stock outstanding	8,878,000	4,926,000
Basic and diluted net loss per share	$ (4.17)	$ (5.71)
Potentially dilutive securities consist of:
Outstanding common stock options	308,000	201,000
Outstanding preferred stock option	829,000	829,000
Common Stock Purchase Warrants	12,810,000	311,000
Related party liability	401,000	20,000
Convertible senior secured promissory notes and accrued interest	12,382,000
Potentially dilutive securities	34,571,000	2,030,000
Series C Preferred Stock [Member]
Potentially dilutive securities consist of:
Convertible preferred stock	5,000	5,000
Series D Preferred Stock [Member]
Potentially dilutive securities consist of:
Convertible preferred stock		289,000
Series E Preferred Stock [Member]
Potentially dilutive securities consist of:
Convertible preferred stock	1,302,000	375,000
Series H Preferred Stock [Member]
Potentially dilutive securities consist of:
Convertible preferred stock	6,534,000

Commitments and Contingencies55

Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies [Abstract]
2,016	$ 150
Total	$ 150

Commitments and Contingencies56

Commitments and Contingencies (Details 1) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies [Abstract]
2,016	$ 139
Total	$ 139

Commitments and Contingencies57

Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies [Abstract]
Rental expense	$ 407,000	$ 150,000
Annual adjustment	9,000
Monthly rental payment	$ 12,600

Temporary Equity (Details)

Temporary Equity (Details) - Series H Preferred Stock [Member]	12 Months Ended
	Dec. 31, 2015USD ($)shares
Temporary Equity [Line Items]
Total temporary equity | shares
Temporary equity value
Proceeds from sale of Series H preferred stock (in shares) | shares	4,588
Proceeds from sale of Series H preferred stock (value)	$ 3,796,000
Beneficial conversion feature of Series H convertible preferred stock (value)	(1,260,000)
Deemed dividends related to immediate accretion of beneficial conversion feature of Series H convertible preferred stock (Par value)	1,260,000
Fair Value of common stock warrant issued with Series H convertible preferred stock (value)	$ (2,534,000)
Common stock issued in conversion of Series H convertible preferred stock (In shares) | shares	(1,772)
Common stock issued in conversion of Series H convertible preferred stock (Value)	$ (1,772)
Deemed dividend on conversion of Series H convertible preferred stock to common stock (value)	1,301,000
Deemed dividend related to accretion of redemption value	$ 2,363,000
Total temporary equity | shares	2,816
Temporary equity value	$ 3,154,000

Temporary Equity (Details Textu

Temporary Equity (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Temporary Equity (Textual)
Sale of stock for investor		3,055.556
Warrant issued to purchase of common stock		1,299,000
Conversion of stock amount		$ 1,659,000
Redemption value		$ 3,154,000
Series H Preferred Stock [Member]
Temporary Equity (Textual)
Sale of stock for investor	3,056	1,532
Proceeds from sale of Series H preferred stock, net of issuance costs of $0.4 million		4,588
Warrant issued to purchase of common stock	1,299,000	650,896
Gross proceeds from sale of shares	$ 2,400,000	$ 900,000
Conversion of stock, shares issued		1,772
Dividends, Preferred Stock, Stock		$ 1,600,000
Common shares issued in connection with conversion of stock	2,300,000
Derivative liability		$ 1,548
Sale of stock description	Sale of 3,056 (including 10% OID) shares of the Company's 12% Series H Preferred Stock (the "Series H Preferred Stock") and a warrant to purchase 1,299,000 shares of common stock (the "RD Warrant" and together with the Series H Preferred Stock, the "Securities") in a registered direct offering (the "RD Offering"), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $2.4 million, net of $0.3 million of legal fees. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder.
Warrants exercise price description		(i) all shares of common stock underlying the RD Warrant are registered for resale under the Securities Act of 1933, and (ii) the date six (6) months from September 30, 2015 (the earlier to occur of (i) and (ii), the "Initial Exercise Date") and on or prior to the close of business on the five-year anniversary of the Initial Exercise Date at an exercise price of $2.00 per share
Proceeds from sale of Series H preferred stock, net of issuance costs		$ 400,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Warrant [Member] - $ / shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of warrant activities
Number of Warrants Outstanding Beginning balance		310,912	563,689
Number of Warrants Issued in connection with warrant exchange			300,000
Number of Warrants Exercised			(552,777)
Number of Warrants Issued in connection with various financings	[1]	5,046,705
Number of Warrants Reset Warrants	[2]	7,460,353
Number of Warrants Expired and cancellation		(8,020)
Number of Warrants Outstanding Ending balance		12,809,950	310,912	563,689
Weighted Average Exercise Price Outstanding Beginning Balance		$ 18	$ 9
Weighted Average Exercise Price Issued in connection with warrant exchange			18
Weighted Average Exercise Price Exercised			9
Weighted Average Exercise Price Issued in connection with various financings	[1]	2
Weighted Average Exercise Price Reset Warrantss	[2]	0.71
Weighted Average Exercise Price Expired and cancellation		9
Weighted Average Exercise Price Outstanding Ending Balance		$ 1.14	$ 18	$ 9
Weighted Average Remaining Contractual Term Outstanding		4 years 9 months 7 days	3 years 22 days	1 year 8 months 9 days
[1]	Approximately 4,547,000 warrants contain "down round protection" and the Company classifies these warrant instruments as liabilities at their fair value and adjusts the instruments to fair value at each reporting period.
[2]	Certain warrants contain aggregate exercise provisions, and upon a reset the exercise price is decreased and the amount of common stock available under the warrant agreement increases. During the 4th quarter a reset occurred decreasing the exercise price from $2.00 to $0.71 and increasing the amount of common stock available to be issued from 4,106,000 to 11,566,000

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Jul. 09, 2015	Nov. 07, 2014	Jul. 31, 2015	Jul. 10, 2015	Nov. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity (Textual)
Proceeds from sale of stock					$ 3,000,000	$ 20,000,000
Stock price per share						$ 6
Conversion of stock amount										$ 1,659,000
Conversion of stock, description										The conversion price if converted , would be $0.64 related to the note and accrued interest on the note and would convert to approximately 400,000 shares.
Additional common stock share issued										1,416,000
Common stock, shares authorized							35,000,000			35,000,000	35,000,000
Common stock, stated value							$ 0.001			$ 0.001	$ 0.001
Warrant issued to purchase of common stock										1,299,000
Exercise price							$ 0.40			$ 0.40
Volatility rate										262.00%	288.00%
Risk free interest rate										2.00%	2.00%
Weighted-average expected term										6 years 2 months 5 days	5 years 9 months 18 days
Number of warrants contain down round protection							4,547,000			4,547,000
Notes Payable Securities Purchas Agreement [Member]
Stockholders' Equity (Textual)
Beneficial conversion feature	$ 600,000
LPC Purchase Agreement [Member]
Stockholders' Equity (Textual)
Proceeds from sale of stock						$ 20,000,000
Stock price per share						$ 6
Share purchase price description						The Company may also request that LPC purchase shares under an accelerated purchase notice whereby the per share purchase price will be the lower of (i) 94% of a volume weighted average price calculation as determined under the LPC Purchase Agreement or (ii) the closing price of the common stock on the accelerated purchase date.
Initial share purchase value						$ 400,000
Initial share purchase						26,667
Number of shares sold									256,305
Common shares issued as a commitment fee, value									$ 2,800,000		$ 500,000
Common shares issued as a commitment fee									3,290		40,000
Common Stock [Member]
Stockholders' Equity (Textual)
Conversion of stock amount										$ 3,000
Conversion of stock, shares issued										3,415,574
Common stock, shares authorized							35,000,000			35,000,000
Common shares issued as a commitment fee						63,333
Common stock issued for services, Shares										526,388	50,971
Service cost										$ 700,000
Commitment fee shares, description						The Company issued 63,333 shares of common stock to LPC (the 'Commitment Fee Shares'), 40,000 upon entering into the agreement and 23,333 contingently issuable on a pro rata basis as the Company utilizes the financing arrangement.
Agreement termination date						Aug. 31, 2016
Warrant [Member]
Stockholders' Equity (Textual)
Warrant issued to purchase of common stock										500,000
Fair value of warrants										$ 600,000
Exercise price							$ 0.01			$ 0.01
Volatility rate										250.00%
Risk free interest rate										1.00%
Weighted-average expected term										5 years
Minimum [Member]
Stockholders' Equity (Textual)
Common stock convertible conversion price										$ 0.90
Increasing amount of common stock to be issued							4,106,000
Minimum [Member] | Warrant [Member]
Stockholders' Equity (Textual)
Exercise price							$ 0.71			0.71
Maximum [Member]
Stockholders' Equity (Textual)
Common stock convertible conversion price										3.40
Increasing amount of common stock to be issued							11,566,000
Maximum [Member] | Warrant [Member]
Stockholders' Equity (Textual)
Exercise price							$ 2			$ 2
Series G Preferred Stock [Member]
Stockholders' Equity (Textual)
Proceeds from sale of stock								$ 5,000,000
Stock issued during period shares								1,087
Additional preferred stock issued as a fee				100
Preferred stock shares conversion price				$ 9
Repurchase of common stock										$ 4,750
Conversion of stock amount										$ 1,900,000
Conversion of stock, shares issued										201,112
Conversion of stock, description										In addition, the holders upon conversion received a conversion premium amount based on an agreed upon dividend rate which ranged 13-24% and six years from the date of notice of exercise.
Preferred stock original issue discount rate								8.00%
Conversion of common stock								1,087
Gross proceeds from sale of shares										$ 2,000,000
Initial share purchase				435
Series D Preferred Stock [Member]
Stockholders' Equity (Textual)
Preferred stock original issue discount rate											10.00%
Beneficial conversion feature											$ 321
Common stock issued as a dividend due upon conversion									2,045
Common stock issued dividend								3,620	7,819
Original issue discount amount											130
Series E Convertible Preferred Stock [Member]
Stockholders' Equity (Textual)
Proceeds from sale of stock										4,700,000	$ 3,500,000
Stock issued during period shares											3,944
Conversion of stock amount										$ 700,000
Conversion of stock, shares issued			766							766
Preferred stock original issue discount rate											10.00%
Beneficial conversion feature											$ 376
Common stock issued dividend										1,003,433
Conversion of common stock											3,944
Original issue discount amount											$ 450
Preferred stock issuance costs											$ 43,000
Preferred stock issuance costs share											556
Demand promissory note											$ 500,000
Additional preferred stock share issued										5,250
Preferred stock shares after amendment price per share							$ 7.50			$ 7.50
Preferred stock, liquidation preference, value							$ 12,480,000			$ 12,480,000	$ 12,480,000
Series E Convertible Preferred Stock [Member] | Notes Payable Securities Purchas Agreement [Member]
Stockholders' Equity (Textual)
Conversion of stock amount		$ 1,000
Conversion of stock, shares issued		4,500
Preferred stock original issue discount rate		12.00%

Stock Option Plans (Details)

Stock Option Plans (Details) - $ / shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
2008 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance		143,974	46,275
Common stock option outstanding - Options granted, Employee	[1]		83,333
Common stock option outstanding - Options granted, Non-employee			22,009
Common stock option outstanding - Options granted, Options cancelled		(30,000)	(7,643)
Option Outstanding - Ending Balance		113,974	143,974	46,275
Options vested December 31, 2015		104,891
Weighted Average Exercise Price - Beginning Balance		$ 11.50	$ 7.50
Weighted Average Exercise Price - Options granted, Employee	[1]		13.50
Weighted Average Exercise Price - Options granted, Non-employee			12
Weighted Average Exercise Price - Options granted ,Options cancelled		15	10.50
Weighted Average Exercise Price - Ending Balance		$ 10.58	$ 11.50	$ 7.50
Weighted Average Remaining Contractual Term - Options granted, Employee	[1]		8 years 2 months 12 days
Weighted Average Remaining Contractual Term - Options granted, Non-employee			8 years 2 months 12 days
Weighted Average Remaining Contractual Term - Ending Balance		8 years 6 months	7 years 9 months 18 days	8 years
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance		57,333
Common stock option outstanding - Options granted, Employee		166,467	57,333
Common stock option outstanding - Options granted, Non-employee		15,000
Common stock option outstanding - Options granted, Options cancelled		(44,600)
Option Outstanding - Ending Balance		194,200	57,333
Options vested December 31, 2015		83,922
Weighted Average Exercise Price - Beginning Balance		$ 13.50
Weighted Average Exercise Price - Options granted, Employee		12.50	$ 13.50
Weighted Average Exercise Price - Options granted, Non-employee		12.30
Weighted Average Exercise Price - Options granted ,Options cancelled		12
Weighted Average Exercise Price - Ending Balance		$ 8.91	$ 13.50
Weighted Average Remaining Contractual Term - Options granted, Employee		8 years 2 months 12 days	8 years 9 months 18 days
Weighted Average Remaining Contractual Term - Options granted, Non-employee		8 years 2 months 12 days
Weighted Average Remaining Contractual Term - Ending Balance		9 years 6 months	8 years 9 months 18 days	0 years
2012 Preferred Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance		2,487,500	2,287,500
Preferred stock option outstanding - Options granted, Employee			200,000
Option Outstanding - Ending Balance		183,050	2,487,500	2,287,500
Options vested December 31, 2015		2,483,333
Weighted Average Exercise Price - Beginning Balance		$ 0.61	$ 0.47
Weighted Average Exercise Price - Options granted, Employee			2.21
Weighted Average Exercise Price - Ending Balance		$ 11.37	$ 0.61	$ 0.47
Weighted Average Remaining Contractual Term - Options granted, Employee			8 years 6 months
Weighted Average Remaining Contractual Term - Ending Balance		7 years 9 months 18 days	8 years 9 months 18 days	7 years 6 months
[1]	Includes 26,666 shares granted to Robert Farrell, the Company's Chief Financial Officer, 13,333 of which are performance-based and vest upon continued service and achievement of a specific goal; and 13,333 of which are market-based and vest upon continued service and the Company's achievement of certain stock price targets. All of these shares have an exercise price of $12.00.

Stock Option Plans (Details 1)

Stock Option Plans (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,470	$ 1,302
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	455	412
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,015	$ 890

Stock Option Plans (Details 2)

Stock Option Plans (Details 2)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock Option Plans [Abstract]
Weighted-average volatility	262.00%	288.00%
Weighted-average expected term	6 years 2 months 5 days	5 years 9 months 18 days
Expected dividends	0.00%	0.00%
Risk-free investment rate	2.00%	2.00%
Expected forfeiture rate	0.00%	0.00%

Stock Option Plans (Details Tex

Stock Option Plans (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Nov. 04, 2012	Aug. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
2008 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted			307,466
Options granted contractual life			10 years
Grant date			4 years
Exercise price			$ 12
Amount of awards available to grant			38,977
Fair value of weighted-average options granted				$ 0.08
2008 Stock Plan [Member] | Robert Farrell [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted			26,666
2008 Stock Plan [Member] | Robert Farrell [Member] | Performance-based [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted			13,333
2008 Stock Plan [Member] | Robert Farrell [Member] | Market-based [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted			13,333
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted		1,025,868
Options granted contractual life		10 years
Grant date		4 years
Amount of awards available to grant			831,668
2012 Preferred Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares granted	8,000
Amount of awards available to grant			512,500
Unrecognized compensation cost			$ 2
Expected weighted-average period			2 years 4 months 24 days
Common stock, conversion description			Each share of Series B Preferred stock converts into 0.33 shares of common stock

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Loss before income taxes
United States	$ (25,213)	$ (27,277)
Foreign
Total Income (Loss) before income taxes	$ (25,213)	$ (27,277)

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of components of income tax expense (benefit)
Federal tax expense (benefit) at statutory rate	$ (8,572)	$ (9,274)
State tax expense (benefit), net of federal tax effect	(1,342)	(1,334)
R&D credit	(326)	(269)
Non-deductible expenses	915	1,696
Change in valuation allowance	$ 9,345	$ 9,181
Total tax expense
Federal tax expense (benefit) at statutory rate	(34.00%)	(34.00%)
State tax expense (benefit), net of federal tax effect	(5.30%)	(4.90%)
R&D credit	(1.30%)	(1.00%)
Non-deductible expenses	3.60%	6.20%
Change in valuation allowance	37.00%	33.70%
Total tax expense

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Components of deferred tax assets
Net operating loss carry-forward	$ 23,241	$ 12,835
Tax credit carry-forward	857	504
Accrued liabilities	1,851	1,257
Capitalized start-up costs	15	15
Depreciation and amortization	3,206	2,833
Gross deferred tax assets	29,170	$ 17,444
Intangibles	(1,113)
Valuation allowance	(29,170)	$ (17,444)
Net deferred tax liabilities	$ 1,113

Income Taxes (Details 3)

Income Taxes (Details 3) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Income Taxes [Abstract]
Ending balance at December 31, 2014	$ 62
Increase (decrease) of unrecognized tax benefits taken in prior years
Increase (decrease) of unrecognized tax benefits related to current year	$ 41
Increase (decrease) of unrecognized tax benefits related to settlements
Reductions to unrecognized tax benefits related lapsing statute of limitations
Ending balance at December 31, 2015	$ 103

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Taxes (Textual)
Statutory federal income tax rate	(34.00%)	(34.00%)
Valuation allowance of deferred tax assets	$ 9,345,000	$ 9,181,000
Total amount of unrecognized tax benefits	0
Federal [Member]
Income Taxes (Textual)
Operating loss carry forwards	$ 58,300,000
Operating loss carry forwards expiration, Description	Beginning in 2028.
State and Local [Member]
Income Taxes (Textual)
Operating loss carry forwards	$ 32,500,000
Operating loss carry forwards expiration, Description	Beginning in 2028.
Federal Research and Development Credit Carry Forwards [Member]
Income Taxes (Textual)
Tax credit carry-forwards	$ 700,000
Tax credit expiration, Description	Beginning in 2029.
State Research and Development Credit Carry Forwards [Member]
Income Taxes (Textual)
Tax credit carry-forwards	$ 200,000
Tax credit expiration, Description	Beginning in 2029.

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Related party liabilities:
Promissory note, 2% interest	$ 222	$ 222
Accrued interest	35	30
Total	$ 257	$ 252

Related-Party Transactions (D72

Related-Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 02, 2015
Related-Party Transactions (Textual)
Conversion price if converted	The conversion price if converted , would be $0.64 related to the note and accrued interest on the note and would convert to approximately 400,000 shares.
Promissory note interest rate	2.00%
Neuro Assets [Member]
Related-Party Transactions (Textual)
Consulting Fees	$ 600,000	$ 700,000
Joseph Rubinfeld [Member]
Related-Party Transactions (Textual)
Consulting Fees	$ 100,000	$ 142,000
Convertible Debt [Member] | Joseph Rubinfeld [Member]
Related-Party Transactions (Textual)
Unsecured Debt			$ 25,000
First right refusal additional obligations			$ 25,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

May. 11, 2016

Jul. 09, 2015

Nov. 07, 2014

Feb. 19, 2016

Sep. 30, 2015

Jul. 31, 2015

Nov. 30, 2014

Mar. 31, 2014

May. 13, 2016

Dec. 31, 2015

Dec. 31, 2014

May. 19, 2016

Jun. 30, 2015

Mar. 31, 2015

Subsequent Event [Line Items]

Common stock, shares issued

21,177,353

5,615,000

Conversion of stock, description

The conversion price if converted , would be $0.64 related to the note and accrued interest on the note and would convert to approximately 400,000 shares.

Common stock issued, value

$ 3,000,000

$ 20,000,000

Interest rate

2.00%

Warrant exercise price

$ 0.40

Warrant exercisable term

5 years

Investment from investors

$ 50,000

Conversion of stock amount

$ 1,659,000

Principal amount

$ 105,000

Notes Payable Securities Purchas Agreement [Member]

Subsequent Event [Line Items]

Maturity Date

Jul. 9, 2016

Interest rate

12.00%

Percentage senior secured convertible notes

12.00%

Principal amount

$ 1,000,000

Common Stock [Member]

Subsequent Event [Line Items]

Conversion of stock, shares issued

3,415,574

Conversion of stock amount

$ 3,000

Common stock issued for services, shares

526,388

50,971

Series H Preferred Stock [Member]

Subsequent Event [Line Items]

Proceeds from sale of shares, value

$ 2,400,000

$ 900,000

Common shares issued in connection with conversion of stock

2,300,000

convertible note issued

$ (1,772)

Conversion of stock, shares issued

1,772

Sale of stock description

Sale of 3,056 (including 10% OID) shares of the Company's 12% Series H Preferred Stock (the "Series H Preferred Stock") and a warrant to purchase 1,299,000 shares of common stock (the "RD Warrant" and together with the Series H Preferred Stock, the "Securities") in a registered direct offering (the "RD Offering"), subject to customary closing conditions. The gross proceeds to the Company from the RD Offering were $2.4 million, net of $0.3 million of legal fees. Each share of Series H Preferred Stock has a stated value of $1,000 and is convertible into shares of common stock at an initial conversion price of the lower of (i) $2.50, subject to adjustment and (ii) 75%, subject to adjustment, of the lowest volume weighted average price, or VWAP, during the fifteen (15) Trading Days immediately prior to the date a conversion notice is sent to the Company by a holder, at any time at the option of the holder.

Series E Preferred Stock [Member]

Subsequent Event [Line Items]

Common shares issued in connection with conversion of stock

1,400

Conversion of common stock

3,944

Percentage of OID

10.00%

Common stock issued, value

$ 4,700,000

$ 3,500,000

Common stock issued, shares

3,944

Interest rate

12.00%

12.00%

12.00%

12.00%

Conversion of stock, shares issued

766

766

Conversion of stock amount

$ 700,000

Series E Preferred Stock [Member] | Notes Payable Securities Purchas Agreement [Member]

Subsequent Event [Line Items]

Percentage of OID

12.00%

Conversion of stock, shares issued

4,500

Conversion of stock amount

$ 1,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Common stock issued for services, shares

500,000

Subsequent Event [Member] | Senior Secured Convertible Promissory Notes [Member]

Subsequent Event [Line Items]

Investment Warrants, Exercise Price

$ 0.40

Purchase of warrants

$ 1,400,000,000

Senior secured convertible promissory notes, Description

On May 13, 2016, two institutional investors purchased $1,540,000 (including 10% OID) principal amount of 10% Senior Secured Convertible Promissory Notes due May 13, 2017 (the “Senior Secured Notes”) pursuant to a previously disclosed Securities Purchase Agreement (the “Notes SPA”) entered into on April 14, 2016.

Subsequent Event [Member] | Amarantus Diagnostics Inc [Member]

Subsequent Event [Line Items]

Sale of shares

80,000,000

Conversion price

$ 0.20

Interest rate

12.00%

Trading securities

$ 50,000

Percentage of outstanding capital stock

100.00%

Business combination, Description

Each share of Avant common stock received in connection with the AMDX Acquisition shall be subject to a lock-up beginning on the Effective Date and ending on the earlier of (i) eighteen (18) months after such date or (ii) a Change in Control (as defined in the Exchange Agreement).

Minimum percentage of conversion of issued and outstanding shares

4.99%

Sales amount

$ 5,000,000,000

Sale of stock description

At the end of the Lock-Up Period, in the event that the AMDX Consideration has a value equal to or less than $3,000,000 in the aggregate on the date the Lock-Up Period expires (based on the average closing “print’ prices at 4:00 p.m. of the Buyer’s common stock on the last five days prior to the date the Lock-Up Period expires as listed or quoted on any national securities exchange or over-the-counter market (including any tier maintained by the OTC Markets, Inc.), as the case may be (the “ Lock-Up Termination Date Closing Price Lock-Up Termination Date Additional Common Stock

Escrow shares

1,500,000

Principal amount

$ 50,000,000

Conversion price

$ 0.20

Senior secured notes

$ 1,540,000,000

Common stock dividends, shares

7,250,000

Escrow, Description

The remaining 74 million of the Escrow Shares can be sold and assigned by Amarantus; provided that no less than 70% of the net proceeds from any sale shall be used to repay certain notes of Amarantus or redeem outstanding shares of preferred stock.

Subsequent Event [Member] | Amdx Sale [Member] | Amarantus Diagnostics Inc [Member]

Subsequent Event [Line Items]

Business combination, Description

During the thirty-six (36) months from May 11, 2016 (the “ Measurement Period ® Additional AMDX Consideration Lock-Up Period

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Debt conversion converted instrument amount

$ 2,000,000

Common stock shares converted

3,800,000

Subsequent Event [Member] | Series H Preferred Stock [Member]

Subsequent Event [Line Items]

Sale of shares

525

Proceeds from sale of shares, value

$ 500,000

Conversion of common stock

1,605

Warrant exercise price

$ 0.40

Subsequent Event [Member] | Series H Preferred Stock [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Conversion of common stock

28,800,000

Common stock issued, shares

28,800,000

Preferred stock dividends, shares

2,300,000

Subsequent Event [Member] | Series E Preferred Stock [Member]

Subsequent Event [Line Items]

Conversion of common stock

1,365

Subsequent Event [Member] | Series E Preferred Stock [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Conversion of common stock

17,100,000

Common stock issued, shares

17,100,000

Preferred stock dividends, shares

2,100,000